

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047519 A2**

(51) International Patent Classification<sup>4</sup>:

C12Q

(74) Agent: SHMUEL, Livnat; McKenna Long & Aldridge  
LLP, 1900 K Street, N.W., Washington, DC 20006 (US).

(21) International Application Number:

PCT/US2004/036555

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

4 November 2004 (04.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/516,730 4 November 2003 (04.11.2003) US


(71) Applicant (for all designated States except US): VAN ANDEL RESEARCH INSTITUTE [US/US]; 333 Bostwick, N.E., Grand Rapids, MI 49503 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,

[Continued on next page]


(54) Title: LSAMP AND NORE 1 DOWN-REGULATION IN CLEAR CELL RENAL CELL CARCINOMAS

A



(57) Abstract: Two genes, *LSAMP* and *NORE1* are under expressed or downregulated in one type of kidney cancer, clear cell renal cell carcinoma (CC-RCC). Methods and kits for detecting cells with this property as tumor cells or as precancerous susceptible cells are disclosed. Also disclosed are methods for inhibiting cancer-associated properties of such cells and for treating subjects in whom such cells are present.

B





SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *without international search report and to be republished upon receipt of that report*

## ***LSAMP* AND *NORE1* DOWN-REGULATION IN CLEAR CELL RENAL CELL CARCINOMAS**

### **BACKGROUND OF THE INVENTION**

#### **Field of the Invention**

5           The present invention in the field of genetics and medicine relates to the under-expression of two genes, *LSAMP* and *NORE1* in clear cell renal cell carcinoma (CC-RCC) tissue and exploitation of this property in methods for detecting or treating this type of cancer.

#### **Description of the Background Art**

10           Renal carcinoma is known to have different histological types, with distinct genetic profiles (Storkel *et al.*, 1997). Worldwide, approximately 150,000 people are diagnosed with renal carcinoma, resulting in 78,000 deaths annually (Zbar *et al.*, 2002). The most common type is clear cell renal cell carcinoma (CC-RCC). Studies of familial CC-RCC have led to the identification of important tumor suppressor genes such as *VHL* (Latif *et al.*, 1993). Recently, position cloning also resulted in the discovery of other kidney cancer-related genes *BHD*, *FH*,  
15           and *HRPT2* (Nickerson *et al.*, 2002; Tomlinson *et al.*, 2002; Carpten *et al.*, 2002). While hereditary CC-RCCs are mainly attributed to *VHL* mutations, there are known CC-RCC families and a significant proportion of sporadic CC-RCCs that are not associated with the *VHL* (Teh *et al.*, 1997; Woodward *et al.*, 2000), thus pointing to the existence of other CC-RCC-related genes. Since some CC-RCC families are associated with balanced chromosomal translocations,  
20           the translocation breakpoint-spanning genes are likely CC-RCC-related candidate genes. The first CC-RCC family with a balanced chromosomal translocation t(3;8)(p14;q24) was described by Cohen *et al.* (1979). To date, at least eight such hereditary CC-RCC-related chromosomal translocation families have been reported (Cohen *et al.*, 1979; Kovacs *et al.*, 1988; Kovacs *et al.*, 1989; Koolen *et al.*, 1998; van Kessel *et al.*, 2001; Podolski *et al.*, 2001; Kanayama *et al.*, 2001).  
25           Interestingly, translocation in all these CC-RCC families is linked to chromosome 3, making constitutional chromosome 3 translocation a predisposing factor (van Kessel *et al.*, 1999; Bodmer *et al.*, 1998; Bodmer *et al.*, 2002c). The subsequent observation of the loss of translocation derivative chromosome 3 (der(3) chromosome) and somatic *VHL* mutations in a proportion of familial tumors led to the proposal of a three-step model of CC-RCC  
30           tumorigenesis (Schmidt *et al.*, 1995; Bodmer *et al.*, 1998; Bodmer *et al.*, 2002c): initial constitutional chromosome 3 translocation, subsequent somatic loss of the der(3) chromosome

leading to the loss of a copy of *VHL*, and a third hit in the form of random somatic mutation in the second *VHL* allele. However, loss of the der(3) chromosome was observed only in a subset of the examined samples. Most of the analyzed familial tumors with loss of the der(3) did not carry *VHL* mutations. Furthermore, neither der(3) loss nor *VHL* mutations were observed in several tumor biopsies in the affected families (Eleveld *et al.*, 2001; Bodmer *et al.*, 2002b). These observations suggest that the breakpoint-spanning genes in the familial RCC-associated chromosome 3 translocations are also likely implicated in RCC tumorigenesis or act synergistically in the above model in the form of genetic and/or epigenetic alternations.

Analysis of the constitutional t(3;8)(p14;q24) translocation associated with familial CC-RCC led to the identification and extensive investigation of the breakpoint-spanning gene *FHIT* (fragile histidine triad) on 3p14 (Ohta *et al.*, 1996). *FHIT* is thought to be a putative tumor suppressor gene, and aberrant *FHIT* transcripts and *FHIT* genomic lesions were observed in a variety of primary tumors and tumor-derived cell lines (Ohta *et al.*, 1996; Siprashvili *et al.*, 1997; Druck *et al.*, 1997). The partner breakpoint-spanning gene *TRC8* on the chromosome 8 shows high homology to the *Drosophila* patched (*PTCH*) gene and probably also functions as a tumor suppressor (Gemmell *et al.*, 2002). Also, another two breakpoint-spanning genes, *DIRC1* on chromosome 2q33 and *DIRC2* on 3q21, disrupted respectively in t(2;3)(q33;q21) and t(2;3)(q35;q21) breakpoints, have been identified (Druck *et al.*, 2001; Bodmer *et al.*, 2002a). The role of these genes in CC-RCC tumorigenesis remains to be determined.

The present inventors describe here the positional cloning of the t(1;3)(q32.1;q13.3) chromosomal breakpoints and the identification of two breakpoint-spanning genes, *LSAMP* on 3q13.3 and *NORE1* on 1q32.1, in a previously reported Japanese hereditary CC-RCC family (Kanayama *et al.*, 2001). *LSAMP* (limbic-system-associated membrane protein gene) encodes a neuronal surface glycoprotein that belongs to the IgLONs (immunoglobulin LSAMP, OPCML/OBCAM, and neurotrimin) family and is distributed in cortical and subcortical regions of the limbic system (Pimenta *et al.*, 1996). To date, very little is known about *LSAMP* and its biological role remains unclear. However, its family partner gene *OPCML/OBCAM* on 11q25 was recently found to be epigenetically inactivated and was regarded as a candidate TSG in epithelial ovarian cancer (Sellar *et al.*, 2003). *NORE1* was recently identified as a homolog of the tumor suppressor gene *RASSF1* at 3p21.3, which is frequently inactivated via promoter hypermethylation in a variety of human tumors (Dammann *et al.*, 2000; Tommasi *et al.*, 2002). The mouse counterpart Nore1 is a Ras effector (Vavvas *et al.*, 1998).

### **BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1 and its subparts** show mapping of the of the t(1;3) breakpoints on chromosomes 1q32.1 and 3q13.3 by FISH.

**Fig. 1A-1** shows the construction of a contig of nine BAC clones in a 3.6-cM region of 1q32.1 (left panel, labeled "1q"). The RP11-54L22 was first found to span the breakpoint by FISH split assay. Overlapped BAC clones (CTD-2245C1, -2321B11, and -2278G17) also showed split signals and confine the der(1) breakpoint region to about 30 kb (dotted box).

**Fig. 1A-2** shows the similar establishment of a contig of ten BAC clones within a 5-cM region of 3q13.3 (right panel, labeled "3q"). The breakpoint was found within RP11-281N16 and was further mapped to a about 30-kb region (dotted box) using overlapping clones (RP11-149B11, CTD-2246M24, and -2514L8).

**Fig. 1B** shows fine mapping of the 1q32.1 and 3q13.3 breakpoints by Southern blot analysis and restriction mapping. Nine specific DNA probes (4-10 kb) flanking the 1q breakpoint were synthesized by long-range PCR with specific primers from known-sequence RP11-54L22 and -281N16. Southern blot analyses showed that a 5.6-kb 1q-p4 probe (**Fig. 1B-1** - left panel, labeled "RP11-54L22 clone") and a 6.2-kb 3q-p2 probe (**Fig. 1B-2** - right panel, labeled "RP11-281N16 clone") span the respective 1q32.1 and 3q13.31 breakpoints, which narrowed both breakpoint regions to approximately 6 kb. Restriction mapping refined the 1q and the 3q breakpoints to about 1.5-kb (**Fig. 1B-1**, left panel) and 2-kb regions, respectively (**Fig. 1B-2**, right panel).

**Fig. 1C** shows representative Southern-blot analyses from both chromosomes showing distinct aberrant bands (indicated by arrowheads) after restriction digestion. DNA from two normal controls (N1, N2) and two patients (FRCC3 and FRCC5) were completely digested and subjected to DNA hybridization analysis. **Fig. 1C-1** shows the Southern blot from chromosome 1q32.1; **Fig. 1C-2** shows the Southern blot from chromosome 3q13.3.

**Figure 2** shows the cloning of both der(1) (1q32.1) and der(3) (3q13.31) breakpoints through long-range PCR and DNA sequencing.

**Fig. 2A** shows amplification of der(1) and der(3) breakpoints via long-range PCR. A 2.15-kb der(1) breakpoint fragment (der(1)-BP) and a 3.25-kb der(3) breakpoint fragment (der(3)-BP) were amplified. The breakpoint fragments were sequenced and are shown in the lowest boxes. The normal sequences around the breakpoints on 1q32.1 and 3q13.31 are also

shown for comparison. The uppercase sequences are from 1q32.1 and the lowercase sequences are from 3q13.31. The sequences in red on 3q13.31 are deleted from the breakpoints.

Fig. 2B is a schematic illustration of the identification of breakpoint-spanning genes. The translocation breakpoints occur within intron 2 of both breakpoint-spanning genes *LSAMP* at 1q32.1 and *NORE1* at 3q13.31, which is accompanied by loss of 52 or 54 bp (red sequences in panel A) from *LSAMP* and of 2 or 0 bp from *NORE1*. An insertion of nucleotide G (ins G) in the breakpoint junction and a loss of 2 bp (delTG) in *LSAMP* in the distal part of breakpoint were also observed. *NORE1* has two isoforms, *NORE1A* and *NORE1B*. *LSAMP* contains seven exons and sits in the reverse strand of chromosome 3.

Figure 3 shows lower expression and promoter methylation of *LSAMP* and *NORE1A* in RCC cell lines and sporadic RCC tumors.

Fig. 3A shows that the expression of *LSAMP* (Fig. 3A-1) and *NORE1A* (Fig. 3A-3) in nine RCC cell lines and sporadic tumors (*LSAMP*;  $0.06 \pm 0.06$  for cell lines and  $0.05 \pm 0.07$  for tumors; *NORE1A*:  $0.19 \pm 0.10$  for cell lines and  $0.27 \pm 0.12$  for tumors) is significantly lower than that in nine normal kidney tissues (*LSAMP*;  $0.77 \pm 0.28$ ; *NORE1A*;  $1.03 \pm 0.53$ ) using real-time PCR assay (*t*-test of SSPS,  $p < 0.001$ ). Fig. 3A-2 and Fig. 3A-4 (Right panels) show eight RCC cell lines which were demethylated using 5-aza-CdR; the expression of both *LSAMP* (Fig. 3A-2) and *NORE1A* (Fig. 3A-4) was significantly increased in each line (*LSAMP*; untreated,  $0.35 \pm 0.23$ ; 5-aza-CdR,  $1.02 \pm 0.33$ ; *NORE1*; untreated,  $0.03 \pm 0.02$ ; 5-aza-CdR,  $0.24 \pm 0.10$ ) (*t*-test of SSPS,  $p < 0.001$ ).

Fig. 3B shows methylation analysis of the *LSAMP* promoter. Bisulfite-treated DNA from 53 matched pairs of human CC-RCC tumors and normal DNA samples, 9 RCC cell lines, 2 t(1;3)-positive lymphoblastoid cell lines, and 2 control lymphoblastoid cell lines (NC1 and NC2) were amplified and digested with *HhaI*. The *LSAMP* promoter (540 bp) contains 28 CpG islands. The analysed 231-bp fragment of the *LSAMP* promoter contains one *HhaI* site and digestion leads to fragments of 162 bp and 69 bp. Representative aberrant methylation of the *LSAMP* promoter in sporadic and familial CC-RCC samples and in RCC cell lines are shown.

Fig. 3C shows methylation analysis of the *NORE1A* promoter by restriction digestion with *TaqI* in the same cohort of samples. The examined 335 bp of the promoter contains 35 CpG sequences. The methylated fragment contains two *TaqI* sites and digestion results in bands of 202, 123, and 10 bp. The sizes of molecular weight markers (M) are shown on the left. N, normal kidney sample; T, RCC.

**Figure 4** shows suppression of LSAMP, NORE1A, and Nore1 re-expression on cell proliferation characteristics.

**Fig. 4A** shows re-expression and localization of EGFP-LSAMP, -NORE1A, and -Nore1 fusion protein 2 h after microinjection or 24 h after lipid-mediated transfection of *pEGFP-LSAMP*, *-NORE1A*, and *-Nore1* plasmids.

**Fig. 4B** shows a growth inhibition assay. A-498/Caki-1 cells were microinjected with *pEGFP-LSAMP*, *-NORE1A*, *-Nore1*, or *pEGFP-C1/-N1* vector (negative control). Cell proliferation analysis was performed 2 h after microinjection. Cells were counted at the indicated times. The "proliferation index" on the y-axis represents the number of cells counted at those times divided by the number of cells counted 2 h after injection.

**Figure 5 and its subparts** show cytogenetic analysis of the t(1q32.1;3q13.3). **Fig. 5A** shows G-banding and spectral karyotyping analysis. The breakpoints were marked with arrows.

**Fig. 5B** shows representative results of FISH with the BAC clone probes on t(1;3) breakpoint region. **Fig. 5B-1** (Left panel) shows FISH with BAC probe CTD-2321B11 (red signal): a split signal was observed in der(3). **Fig. 5B-2** (Right panel) shows FISH with probe RP11-281N16: split signals (red) equally appeared on both der(1) and der(3). A 1q subtelomeric PAC probe 160H23 (green signal) was used as a control in all the FISH experiments.

**Figure 6 and its subparts** show two *NORE1* alterations identified in sporadic tumors T31 and T24. **Fig. 6A** shows that the codon 189 GTG(Val) was replaced by ATG(Met) in T31. It was also found in 5% of the control chromosomes tested. **Fig. 6B** shows that the codon 248 CGG(Arg) was replaced by CAG(Gln) in T24, which has not been detected in control samples. In *NORE1B*, the affected codon number is 95.

**Figure 7** shows nuclear localization and growth suppression analysis of Nore1. **Fig. 7A** demonstrates that EGFP-Nore1 is predominantly nuclear in Caki-1 cells (RCC cell line), by lipid-mediated transfection using a *pEGFP-Nore1* plasmid and LIPOFECTAMINE 2000 reagent (Invitrogen). EGFP expressed from the empty vector *pEGFP-C1* was both nuclear and cytoplasmic. **Fig. 7B** shows that subcellular fractionation and subsequent Western analysis further indicated that the majority of Nore1 is localized to the nucleus, while a lesser amount appears at the plasma membrane. **Fig. 7C** shows that induction of Nore1 inhibits the growth of 293-T cells. The 293-T cells were transfected with *pIND(SPI)-Nore1* or an empty vector and selected in hygromycin for three weeks. Each point on the growth curve represents the mean of

three individual cell count determinations. Fig. 7D shows western analysis of Nore1 expression; V, vector-transfected cells; M, Nore1/MaxP1-transfected cells.

### **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The inventors demonstrate here that the limbic-system-associated membrane protein (*LSAMP*) gene and the *NORE1* gene are the breakpoint-spanning genes in a familial clear cell renal cell carcinoma (CC-RCC), and that the expression of these genes is down-regulated in RCC cell lines and sporadic CC-RCCs. Furthermore, expression of LSAMP and NORE1A proteins in CC-RCC cell lines is shown to inhibit cell proliferation. Diagnostic and treatment methods based on the above observations are described below.

This invention includes a method for detecting the presence of, or a predisposition (susceptibility) to, a cancer (*e.g.*, CC-RCC) in a subject, comprising detecting, measuring the amount of, or quantitating LSAMP and/or NORE1 gene expression in a sample from the subject, compared to a baseline level of expression, wherein a reduction in the expression of one or both of the genes compared to the baseline level indicates that the subject suffers from, or has a predisposition to, the cancer.

As used herein, a "baseline value" or "baseline amount" includes the amount of expression of an LSAMP or a NORE1 gene in normal tissue, such as from a "pool" of normal subjects who do not suffer from, or who do not exhibit a predisposition to, the cancer. This value can be determined at the same time as the level in a sample from the subject being studied, or it can be available in a reference database such as a reference standard or a generic database.

The expression may be at the level of RNA transcription which can be detected by various means including quantitative hybridization to a suitable probe, or at the level of protein translation, for example by determining the activity of, or the presence of, the protein, using conventional procedures including an immunoassay. Methods for detecting, measuring or quantitating either the RNA or the protein gene product are conventional and routine.

In the following description, reference will be made to various methodologies known to those of skill in the art of immunology, cell biology, and molecular biology. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full. Standard reference works setting forth the general principles of immunology include A.K. Abbas *et al.*, *Cellular and Molecular Immunology* (Fourth Ed.), W.B. Saunders Co., Philadelphia, 2000; C.A. Janeway



*et al.*, *Immunobiology. The Immune System in Health and Disease*, Fourth ed., Garland Publishing Co., New York, 1999; Roitt, I. *et al.*, *Immunology*, (current ed.) C.V. Mosby Co., St. Louis, MO (1999); Klein, J., *Immunology*, Blackwell Scientific Publications, Inc., Cambridge, MA, (1990).

5 Monoclonal antibodies (mAbs) and methods for their production and use are described in Kohler and Milstein, *Nature* 256:495-497 (1975); U.S. Patent No. 4,376,110; Harlow, E. *et al.*, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988); *Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, New York, NY (1980); H. Zola *et al.*, in *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, 1982)); (Kozbor *et al.*, 1983, *Immunol. Today* 4:72 (the human B-cell hybridoma technique), and Cole, *et al.*, 1985, In: *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (the EBV-hybridoma technique to produce human mAbs).

10 Interspecies chimeric antibodies are described, for example, in Cabilly *et al.*, U.S. Patents 4,816,567 (3/28/89) and 6,331,415 (12/18/01); Morrison *et al.*, US Patent 5,807,715 (9/15/98) and Eur. Patent Pub. EP173494 (3/5/86); Taniguchi *et al.*, Eur. Patent Pub. EP171496 (2/19/86); Neuberger *et al.*, PCT Pub. WO86/01533 (3/13/86); Robinson *et al.*, PCT Pub. WO 8702671 (5/7/87); Cabilly *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3273-3277 (1984); Morrison *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6851-6855 (1984); Boulianne *et al.*, *Nature* 312:643-646 (1984); Morrison, *Science*, 229:1202-1207 (1985); Neuberger *et al.*, *Nature* 314:268-270 (1985); Takeda *et al.*, *Nature* 314:452-454 (1985); Oi *et al.*, *BioTechniques* 4:214 (1986); Sun *et al.*, *Proc. Natl. Acad. Sci. USA* 84:214-218 (1987); Liu *et al.*, *J. Immunol.* 139:3521-3526 (1987); Better, M., *et al.*, *Science* 240:1041-1043 (May 20, 1988); and Horwitz, A. H., *et al.*, *Proc. Natl. Acad. Sci. USA* 85:8676-8682 (1988).

25 Single chain antibodies (scFv) are described, for example, in Skerra, A. *et al.* (1988) *Science*, 240: 1038-1041; Pluckthun, A. *et al.* (1989) *Methods Enzymol.* 178: 497-515; Winter, G. *et al.* (1991) *Nature*, 349: 293-299; Bird *et al.*, (1988) *Science* 242:423; Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879; Jost CR *et al.*, *J Biol Chem.* 1994 269:26267-26273. U.S. Patents No. 4,704,692, 4,853,871, 4,946,778, 5,260,203, 5,455,030; and Jost CR *et al.* *J Biol Chem.* 1994 269:26267-26273.

30 Immunoassay methods are also described in Coligan, J.E. *et al.*, eds., *Current Protocols in Immunology*, Sec. 2.4.1, Wiley-Interscience, New York, 1992 or current edition); Butt, W.R. (ed.) *Practical Immunoassay: The State of the Art*, Dekker, New York, 1984; Bizollon, Ch. A.,

ed., *Monoclonal Antibodies and New Trends in Immunoassays*, Elsevier, New York, 1984; Butler, J.E., ELISA (Chapter 29), In: van Oss, C.J. *et al.*, (eds), *IMMUNOCHEMISTRY*, Marcel Dekker, Inc., New York, 1994, pp. 759-803; Butler, J.E. (ed.), *Immunochemistry of Solid-Phase Immunoassay*, CRC Press, Boca Raton, 1991; Weintraub, B., *Principles of Radioimmunoassays*,  
5 Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986; Work, T.S. *et al.*, *Laboratory Techniques and Biochemistry in Molecular Biology*, North Holland Publishing Company, NY, (1978) (Chapter by Chard, T., "An Introduction to Radioimmune Assay and Related Techniques").

10 In a preferred embodiment, the presence or amount of LSAMP and/or NORE1 protein in a cell is detected by binding proteins in the sample to a detectably labeled antibody that is specific for an LSAMP or a NORE1 protein. An antibody "specific" for a polypeptide means that the antibody recognizes a defined sequence of amino acids, or epitope, either present in the full length polypeptide, or in a peptide fragment thereof.

15 Any of a variety of antibodies can be used in such methods. Such antibodies include, polyclonal, monoclonal (mAbs), recombinant, humanized or partially humanized, single chain (scFv), Fab, and fragments thereof. The antibodies can be of any isotype, such as IgM, various IgG isotypes such as IgG<sub>1</sub>, IgG<sub>2a</sub>, *etc.*, and they can be from any animal species that produces antibodies, including goat, rabbit, mouse, chicken or the like.

20 Antibodies are prepared according to conventional methods, which are well known. See, references cited above. Methods of preparing humanized or partially humanized antibodies, and antibody fragments, and methods of purifying antibodies, are conventional (*supra*).

25 For preparation of mAbs, any technique that provides mAbs produced by cell lines in continuous culture can be used (*supra*). Techniques described for the production of single chain antibodies (*supra*) can be adapted to produce scFv antibodies to polypeptide products of this invention.

Transgenic animals may be used to express partially or fully humanized antibodies to immunogenic polypeptide products of this invention.

Other specific binding partners, such as, *e.g.*, aptamers and peptide nucleic acids (PNA), may be used in place of antibodies.

30 The sample to be assayed in a method of the invention may be any suitable cell or tissue, or extract thereof. A sample of a body fluid such as plasma, serum, urine, saliva, cerebrospinal fluid, *etc.*, may be obtained from the subject being screened. Alternatively, cells expressing the

protein on their surface, *e.g.*, suitable neuronal cells for the detection of LSAMP protein, may be obtained by simple, conventional means. If the protein is a receptor or other cell surface structure, it can be detected and quantified by well-known methods such as flow cytometry, immunofluorescence, immunocytochemistry or immunohistochemistry, or the like (see *supra*).

5 In a preferred embodiment, the detection or diagnosis is performed on a sample from a kidney tumor, *e.g.*, a tissue biopsy, a fresh-frozen sample, or a paraffin-embedded tissue section. Methods of preparing all of these sample types are conventional and well known in the art. Biopsy material and fresh-frozen samples can be extracted by conventional procedures to obtain proteins or polypeptides. In one embodiment, paraffin-embedded blocks are sectioned and  
10 analyzed directly without such extraction.

Another embodiment of the invention is a method for inhibiting the growth, transformation or other cancer-associated property of a tumor cell, preferably a CC-RCC cell, which is characterized by reduced expression of the *LSAMP* and/or *NORE1* genes compared to a normal kidney cell or a baseline value. The method comprises contacting the cell with an  
15 effective amount of an agent which stimulates the expression of the LSAMP and/or NORE1 polypeptide. By an "effective amount" is meant an amount that leads to a measurable reduction of such expression measured at the RNA or protein level.. Methods of contacting a cell are conventional and include injection or other forms of administration and may be done using liposomes, electroporation, microinjection or the like. The cell may be contacted *in vitro* or *in*  
20 *vivo*.

Another embodiment is a method for treating a subject suffering from cancer or a tumor, such as CC-RCC, in which at least some of the cells of the subject under-express the *LSAMP* and/or the *NORE1* gene compared to a baseline value. The method comprises

- (1) administering to the subject an effective amount of LSAMP and/or NORE1 polypeptide  
25 or active fragment or variant thereof, or a nucleic acid encoding the polypeptide or active fragment or variant thereof which fragment or variant have the desired biological level of the LSAMP or NORE1 polypeptide; or
- (2) administering an agent which stimulates, promotes or otherwise results in increased expression LSAMP or NORE1 polypeptide.

30 Methods of administering the polypeptide are conventional and include, *e.g.*, systemic administration or, preferentially, direct intratumoral administration. The subject may be any suitable animal, preferably a mammal, more preferably a human.

In the above nucleic acid embodiments, the polynucleotide being administered comprises sequences which encode the polypeptide (or variant or fragment), and which are operably linked to an expression control sequence such as a promoter. This polynucleotide may be cloned in a suitable vector, many examples of which are well known to those of skill in the art.

5 As used herein, the term "expression control sequence" means a polynucleotide sequence that regulates expression of a polypeptide encoded by a polynucleotide to which the control sequence is functionally ("operably") linked. Expression can be regulated at the level of the mRNA or polypeptide synthesis or stability. Thus, the "term expression control sequence" includes mRNA-related elements and protein-related elements, which include promoters,  
10 domains within promoters, upstream elements, enhancers, elements that confer tissue or cell specificity, response elements, ribosome binding sequences, transcriptional terminators, *etc.* An expression control sequence is operably linked to a nucleotide sequence (*e.g.*, a coding sequence) when the expression control sequence is positioned in such a manner to effect or achieve expression of the coding sequence. For example, when a promoter is operably linked 5' to a coding sequence, expression of the coding sequence is driven by the promoter. Suitable  
15 expression control sequences will be evident to the skilled worker.

Methods for generating polynucleotides and polypeptides for use in the methods, compositions and kits of the invention, are conventional. For example, polynucleotides can be isolated, *e.g.*, using sequence probes corresponding to the sequences indicated in the GenBank  
20 accession numbers provided elsewhere herein. The polynucleotides can be cloned into suitable vectors, and introduced into and replicated and/or expressed in suitable host cells. Procedures for carrying out these steps are conventional. Nucleic acids that have replicated in the cells, and polypeptides expressed in the cells, can be harvested and, if desired, purified, using conventional procedures. Some suitable molecular biology methods, for use in these and other aspects of the  
25 invention, are provided *e.g.*, in Sambrook, *et al.* (1989), *Molecular Cloning, a Laboratory Manual*, Cold Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Ausubel *et al.* (1995), *Current Protocols in Molecular Biology*, N.Y., John Wiley & Sons; Davis *et al.* (1986), *Basic Methods in Molecular Biology*, Elsevier Sciences Publishing, Inc., New York; Hames *et al.* (1985), *Nucleic Acid Hybridization*, IL Press; Dracopoli *et al.* *Current Protocols in Human*  
30 *Genetics*, John Wiley & Sons, Inc.; and Coligan *et al.* *Current Protocols in Protein Science*, John Wiley & Sons, Inc.

Methods for providing a polynucleotide to a cell *in vitro*, *i.e.*, contacting the cell, are conventional and include, transfection, a gene gun, microinjection, electroporation, introduction by liposomes or with viral or non-viral vectors, *etc.*

For gene gun-mediated DNA injection, DNA-coated gold particles (*e.g.*, about 1 µg DNA/bullet) are delivered using a helium-driven gene gun (BioRad, Hercules, CA) with a discharge pressure of, for example, about 400 p.s.i. The Biojector 2000 (Bioject Inc., Portland, OR) is a needle-free jet injection device consisting of an injector and a disposable syringe. The orifice size controls the depth of penetration. For example, DNA (at between about 1 and 100 µg) may be delivered using the Biojector with a syringe nozzle. This may be done intradermally, intramuscularly or intratumorally. Follow-up injections using both methods can be repeated as needed, *e.g.*, at weekly intervals.

Methods of gene therapy or nucleic acid therapy, in which a polynucleotide of the invention is provided in a delivery vehicle, are well-known. The gene vehicle may be of viral or non-viral origin (see generally, Jolly, *Cancer Gene Therapy* 1:51-64 (1994) Kimura, *Human Gene Therapy* 5:845-852 (1994); Connelly, *Human Gene Therapy* 1:185-193 (1995); and Kaplitt, *Nature Genetics* 6:148-153 (1994). Vehicles for delivery of nucleic acid constructs including a coding sequence of a therapeutic embodiment of the invention can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches. Expression of the coding sequences can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence can be either constitutive or regulated.

Recombinant retroviruses constructed to carry or express a selected nucleic acid molecule of interest may be used. See, for example, EP 0415731; WO 90/07936; WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218; Vile *et al.*, *Canc Res* 53:3860-3864 (1993); Vile *et al.*, *Canc. Res.* 53:962-967 (1993); Ram *et al.*, *Canc. Res.* 53:83-88 (1993); Takamiya *et al.*, *J. Neurosci. Res.* 33:493-503 (1992); Baba *et al.*, *J. Neurosurg.* 79:729-735 (1993); U.S. Patent No. 4,777,127; GB Patent No. 2,200,651; and EP 0345242. Preferred recombinant retroviruses include those described in WO 91/02805.

Packaging cell lines suitable for use with the above-described retroviral vector constructs may be readily prepared (WO 95/30763 and WO 92/05266), and used to create producer cell lines (also termed vector cell lines) for the production of recombinant vector particles. Preferred

embodiments of the invention utilize packaging cell lines made from human (such as HT1080 cells) or from mink parent cell lines, that result in production of recombinant retroviruses that survive inactivation in human serum.

Alphavirus-based vectors can function as gene delivery vehicles and be constructed from a wide variety of alphaviruses, including, for example, Sindbis virus vectors, Semliki forest virus (ATCC VR-67; ATCC VR-1247), Ross River virus (ATCC VR-373; ATCC VR-1246) and Venezuelan equine encephalitis virus (ATCC VR-923; ATCC VR-1250 ATCC VR-1249; ATCC VR-532). Representative examples of such vector systems are described in U.S. Patents No. 5,091,309; 5,217,879; and 5,185,440; and PCT Publications WO 92/10578; WO 94/21792; WO 95/27069; WO 95/27044; and WO 95/07994.

Delivery vehicles of the present invention can also employ parvovirus such as adeno-associated virus (AAV) vectors. See, for example, Srivastava, WO 93/09239, Samulski *et al.*, *J. Vir.* 63:3822-3828 (1989); Mendelson *et al.*, *Virology* 166:154-165 (1988); and Flotte *et al.*, *P.N.A.S.* 90:10613-10617 (1993).

Representative examples of adenoviral vectors are described by Berkner, *Biotechniques* 6:616-627; Rosenfeld *et al.*, *Science* 252:431-434 (1991); WO 93/19191; Kolls *et al.*, *Proc. Natl. Acad. Sci. USA* 91:215-219 (1994); Kass-Eisler *et al.*, *Proc. Natl. Acad. Sci. USA* 90:11498-11502 (1993); Guzman *et al.*, *Circulation* 88:2838-2848 (1993); Guzman *et al.*, *Cir. Res.* 73:1202-1207 (1993); Zabner *et al.*, *Cell* 75:207-216 (1993); Li *et al.*, *Hum. Gene Ther.* 4:403-409 (1993); Cailaud *et al.*, *Eur. J. Neurosci.* 5: 1287-1291 (1993); Vincent *et al.*, *Nat. Genet.* 5:130-134 (1993); Jaffe *et al.*, *Nat. Genet.* 1:372-378 (1992); and Levrero *et al.*, *Gene* 101:195-202 (1992). Exemplary adenoviral nucleic acid therapy vectors useful herein are described in WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655. Administration of DNA linked to killed adenovirus is described in Curiel, *Hum. Gene Ther.* 3:147-154 (1992).

Other delivery vehicles and methods may be employed, including polycationic condensed DNA linked or unlinked to killed adenovirus alone, for example, Curiel (*supra*); ligand-linked DNA, for example, see Wu, *J. Biol. Chem.* 264:16985-16987 (1989); eukaryotic cell delivery vehicles (U.S.S.N. 08/240,030, filed May 9, 1994, and 08/404,796); deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun (U.S. Patent 5,149,655); ionizing radiation (U.S. Patent No. 5,206,152 and WO 92/11033; nucleic acid charge neutralization or fusion with cell membranes. Additional approaches are described in

Philip, *Mol. Cell Biol.* 14:2411-2418 (1994) and Woffendin, *Proc. Natl. Acad. Sci. USA* 91:1581-1585 (1994) (a mechanical delivery system).

Naked DNA may also be employed. See, for example, WO 90/11092 and U.S. Patent 5,580,859. Uptake efficiency may be improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

Use of liposomes as DNA delivery vehicles are described in U.S. Patent 5,422,120, PCT Patent Pub. WO 95/13796, WO 94/23697 and WO 91/14445, and EP 0 524 968.

Effective dosages and routes of administration of polypeptides or polynucleotides of the invention are conventional. The exact amount (effective dose) of the agent will vary from subject to subject, depending on the species, age, weight and general or clinical condition of the subject, the severity or mechanism of any disorder being treated, the particular agent or vehicle used, the method and scheduling of administration, and the like. A therapeutically effective dose can be determined empirically, by conventional procedures known to those of skill in the art. See, e.g., *The Pharmacological Basis of Therapeutics*, Goodman and Gilman, eds., Macmillan Publishing Co., New York. For example, an effective dose can be estimated initially either in cell culture assays or in suitable animal models. The animal model may also be used to determine the appropriate concentration ranges and routes of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutic dose can also be selected by analogy to dosages for comparable therapeutic agents. In general, effective doses include between about 10 ng to about 100 mg up to a total dose of about 5g, depending on the route of administration, number of repeat administrations and other factors as noted above.

A variety of routes of administration may be used, including oral, respiratory, intranasal, intrarectal, intravaginal, sublingual, transdermal, extracorporeal, topical, intravenous, subcutaneous, intramuscular, intramedullary, or intraperitoneal injection, other parenteral routes, or the like. One of skill in the art will recognize particular cells, tissues or organs into which therapeutic agents of the invention can be administered, as appropriate for particular indications.

Another embodiment of the invention is a pharmaceutical composition comprising (a) an LSAMP and/or NORE1 polypeptide, or an active fragment or variant thereof, or (b) a

polynucleotide encoding an LSAMP and/or NORE1 polypeptide, or encoding an active fragment or variant of the polypeptide, wherein the polynucleotide is operably linked to an expression control sequence; and a pharmaceutically acceptable carrier.

Another embodiment of the invention is a kit, suitable for carrying out any method of the invention. For example, the invention includes a kit for detecting the presence and/or amount of an LSAMP and/or a NORE1 polypeptide in a tumor or pre-cancerous sample, such as CC-RCC or normal kidney cells susceptible of transformation to become CC-RCC, wherein the cells are characterized by a reduced amount compared to a baseline value of one or both of these polypeptides. The kit comprises one or more reagents for detecting the polypeptide, preferably an antibody specific for the polypeptide, which is preferably detectably labeled, and, optionally, one or more reagents for testing the binding of the antibody to a sample polypeptide and/or that one that facilitates detection of antibody binding.

Another embodiment is a kit for detecting the presence and/or amount of a polynucleotide encoding LSAMP and/or NORE1 polypeptide in a tumor or pre-cancerous sample, such as a CC-RCC tumor cells or normal kidney cells susceptible of transformation to become CC-RCC. Such cells are characterized by under-expression of LSAMP and/or NORE1 compared to a baseline value which is indicative that the cells are susceptible of development into cancer cells, primarily CC-RCC cells. The kit comprises a nucleic acid probe specific for a LSAMP- or NORE1-encoding polynucleotide, and, optionally, one or more reagents that facilitate hybridization of the probe to the sample polynucleotide, and/or that facilitate detection of the hybridized polynucleotide.

Another embodiment is a kit useful for inhibiting or reducing a cancer-associated property of a cell, comprising an LSAMP and/or NORE1 polypeptide, or an active fragment or variant thereof, and, optionally, means for introducing the polypeptide into the cell and/or for measuring the cancer-associated property.

In another embodiment, the kit is suitable for treating a subject suffering from a cancer such as CC-RCC, the kit comprising an LSAMP and/or NORE1 polypeptide, or an active fragment or variant thereof, and, optionally, means for administering the polypeptide to the subject.

In other embodiments, the kit comprises, instead of the polypeptides, a nucleic acid encoding LSAMP and/or NORE1, or encoding active fragments or variants of the polypeptides, wherein the polynucleotides are operably linked to expression control sequences.



Optionally, kits of the invention comprise instructions for performing the method for which the kit is intended and/or for analyzing and/or evaluating the assay results as generated by the method. A kit may further comprise a support on which a cell can be propagated (*e.g.*, a tissue culture vessel) or a support to which a reagent used in the method is immobilized. Other optional elements of the present kit include suitable buffers, media components, or the like; reagents for performing suitable controls; a computer or computer-readable medium for storing and/or evaluating the assay results; containers; or packaging materials. The reagents of the kit may be in containers in which the reagents are stable, *e.g.*, in lyophilized form or stabilized liquids. The reagents may also be in single use form, *e.g.*, in single dosage form for use as therapeutics, or in single reaction form for diagnostic use.

Another embodiment of the invention is an antibody specific for an epitope of the LSAMP or the NORE1 polypeptide. Such antibodies are useful, not only for diagnostic procedures, as discussed above, but also for experimental purposes, *e.g.*, for elucidating the mechanisms of CC-RCC carcinogenesis. Some of the types of suitable antibodies, and methods for using them, were discussed above.

## **EXAMPLES**

### **EXAMPLE I**

#### **Mapping of Breakpoints**

The inventors have previously mapped the constitutional t(1;3)-associated breakpoints to bands 1q32.1 and 3q13.3 in a family with four cases of CC-RCC (Kanayama *et al.*, 2001). In this study, the inventors cloned the breakpoints of t(1;3)(q32.1;q13.3) by using a strategy that combined FISH, Southern blot, long-range PCR, and DNA sequencing. FISH experiments allowed narrowing of the breakpoint regions to a 20- to 30-kb range on both affected chromosomes (Figure 1A). These were further refined via Southern blot analyses and restriction mapping to approximately 2 kb (Figure 1B and 1C). Assisted by information from human genome sequence databases and BAC clone databases, several sets of specific primers were designed around the breakpoints and long-range PCR was performed to amplify the breakpoint fragments (Figure 2A). A 2.15 kb der(1)-breakpoint and a 3.25 kb der(3)-breakpoint were amplified and subcloned into TA-cloning vector (Invitrogen, USA) (Figure 2A). Subsequent DNA sequencing of the breakpoint fragments resulted in the identification of both breakpoints (Figure 2; also see Table 1).

Table 1.  
Sequences and positions of the synthetic oligonucleotides used in the study.

Target	Direction	Sequence (5'-3')	SEQ ID NO:
<b>For genomic PCR of the fusion genes</b>			
NORE1-LSAMP	Forward	GGAGAAAGAGAGACCAGGACAAA (NORE1)	1
NORE1-LSAMP	Reverse	GCTTCCCAGGTTCAAGTGATTC (LSAMP)	2
NORE1-LSAMP	Sequencing		3
NORE1-LSAMP	Forward	AGCGATCATCCTGCCTTG (NORE1)	4
NORE1-LSAMP	Sequencing		5
NORE1-LSAMP	Forward	CATGCCAGGCCCATAAATAG (NORE1)	6
NORE1-LSAMP	Sequencing		7
NORE1-LSAMP	Forward	GTGGCCTGCAAAACCTAAC (NORE1)	8
LSAMP-NORE1A	Forward	AATCCAGGTCTCTCTGCTCCAA (LSAMP)	9
LSAMP-NORE1A	Reverse	CTCTGAGTGAGTCACGTGGCTT (NORE1)	10
LSAMP-NORE1A	Forward	CCTTCCTTTTCTCCATAGCACT (LSAMP)	11
LSAMP-NORE1A	Forward	ATTGTGGAAAATGGAGCTTC (LSAMP)	12
<b>For fusion transcript analyses</b>			
NORE1A-LSAMP	Forward	AGTCAGCAGGAGGGTTTATCC (NORE1A)	13
NORE1A-LSAMP	Reverse	CCCTTCCAGTTGGTGTAAGGT (LSAMP)	14
LSAMP-NORE1A	Forward	TTCTCTGGAATACAGCCTCCG (LSAMP)	15
LSAMP-NORE1A	Reverse	GCGTGTTGTAGCTGTCGATC (NORE1A)	16
NORE1B-LSAMP	Forward	GCAGCATGAGCAGTGGGTAC (NORE1B)	17
NORE1B-LSAMP	Reverse	TTGCCTGACTGCTCCCTG (LSAMP)	18
<b>For mutation analyses</b>			
<b>NORE1 gene</b>			19
NORE1A Exon 1	Forward	TCCTTCCTGCCACTCCGACTC	20
NORE1A Exon 1	Reverse	TCCCAAGAACTCACAACAAAACC	21
NORE1A Exon 1	Sequencing		22
NORE1A Exon 1	Forward	TCCTTCCTGCCACTCCGACT	23
NORE1A Exon 1	Sequencing		24
NORE1A Exon 1	Reverse	TCCTCGCGCCTCTGTGTCCC	25
NORE1A Exon 2	Forward	TCCAAGGTTATTTCTCTGGGTG	26
NORE1A Exon 2	Reverse	GAGTTCTCTGTGTCACTTCCCC	27
NORE1A Exon 3	Forward	CTGGATGCTCACTTCTTGGTTAG	28
NORE1A Exon 3	Reverse	CAGAATTCAGAGTGAGGGCAG	29
NORE1A Exon 4	Forward	AGAACTCAAGGAGACAGGTGGG	30

Target	Direction	Sequence (5'-3')	SEQ ID NO:
<i>NORE1A</i> Exon 4	Reverse	AGATCTGAACACCACATGGGC	26
<i>NORE1A</i> Exon 5	Forward	CACCTCTGCATTTCCAATCCTT	27
<i>NORE1A</i> Exon 5	Reverse	GTGGCTCCCACCTATGTGAG	28
<i>NORE1A</i> Exon 6	Forward	CAGGGTCTCTCAGGTCGTGTCA	29
<i>NORE1A</i> Exon 6	Reverse	CCCCCATGCAAACACTTGTC	30
<i>NORE1B</i> Exon1	Forward	CCCGCTGAAAGAAACGCAGG	31
<i>NORE1B</i> Exon1	Reverse	ATGCTCAGCCCTCAGGGCAA	32
<b><i>LSAMP</i> gene</b>			
<i>LSAMP</i> Exon1	Forward	AGTGGAAAGGACCATAAACTGGC	33
<i>LSAMP</i> Exon1	Reverse	TGGAGTTCAAGGAGATCAGACAC	34
<i>LSAMP</i> Exon2	Forward	ATGACATCCATCCACTGGATG	35
<i>LSAMP</i> Exon2	Reverse	TGCAACTCCCACCTCTTCTTA	36
<i>LSAMP</i> Exon3	Forward	AGATGGCAAGCATGGGTCTTA	37
<i>LSAMP</i> Exon3	Reverse	TCAGCAGAATTCCAGGAGCA	38
<i>LSAMP</i> Exon4	Forward	CTGCTTCTGTGGAATCTGATGTC	39
<i>LSAMP</i> Exon4	Reverse	CAAAGACCAAGTCCTGCCCTT	40
<i>LSAMP</i> Exon5	Forward	CTCCCTTCCTGCCTCTCTCTAA	41
<i>LSAMP</i> Exon5	Reverse	GCTTAAGAGCTACAGGCCCC	42
<i>LSAMP</i> Exon6	Forward	TCCTTTTCCTCCAGTGTGAGG	43
<i>LSAMP</i> Exon6	Reverse	TGCTATGCACAGGAGTTGAGAA	44
<i>LSAMP</i> Exon7	Forward	CTTCTTGGGCTGCACATAAGTG	45
<i>LSAMP</i> Exon7	Reverse	ACGGTCTCCCCCATCTCTCT	46
<b><i>VHL</i> gene</b>			
<i>VHL</i> Exon1	Forward	TGTAAAACGACGGCCAGTCGAAGAGTACGGCCCTGAAGA AGAC	47
<i>VHL</i> Exon1	Reverse	CAGGAAACAGCTATGACCCAGTACCCTGGATGTGTCCTG CCTC	48
<i>VHL</i> Exon2	Forward	TGTAAAACGACGGCCAGTAGACGAGGTTTCACCACGTTA GC	49
<i>VHL</i> Exon2	Reverse	CAGGAAACAGCTATGACCGTCCTCTATCCTGTACTTACC AC	50
<i>VHL</i> Exon3	Forward	TGTAAAACGACGGCCAGTCTGAGACCCTAGTCTGCCACT GAGGAT	51
<i>VHL</i> Exon3	Reverse	CAGGAAACAGCTATGACCCAAAAGCTGAGATGAAACAGT GTAAGT	52

Target	Direction	Sequence (5'-3')	SEQ ID NO:
<b><i>For genomic PCR of the fusion genes</i></b>			
NORE1-LSAMP	Forward	GGAGAAAGAGAGACCAGGACAAA ( <i>NORE1</i> )	53
NORE1-LSAMP	Reverse	GCTTCCCAGGTTCAAGTGATTC ( <i>LSAMP</i> )	54
NORE1-LSAMP	Sequencing		55
NORE1-LSAMP	Forward	AGCGATCATCCTGCCTTG ( <i>NORE1</i> )	56
NORE1-LSAMP	Sequencing		57
NORE1-LSAMP	Forward	CATGCCAGGCCCATAAATAG ( <i>NORE1</i> )	58
NORE1-LSAMP	Sequencing		59
NORE1-LSAMP	Forward	GTGGCCTGCAAAACCTAAC ( <i>NORE1</i> )	60
LSAMP-NORE1A	Forward	AATCCAGGTCTCTCTGCTCCAA ( <i>LSAMP</i> )	61
LSAMP-NORE1A	Reverse	CTCTGAGTGAGTCACGTGGCTT ( <i>NORE1</i> )	62
LSAMP-NORE1A	Forward	CCTTCCTTTTCTCCATAGCACT ( <i>LSAMP</i> )	63
LSAMP-NORE1A	Forward	ATTGTGGAAAATGGAGCTTC ( <i>LSAMP</i> )	64
<b><i>For fusion transcript analyses</i></b>			
NORE1A-LSAMP	Forward	AGTCAGCAGGAGGGTTTATCC ( <i>NORE1A</i> )	65
NORE1A-LSAMP	Reverse	CCCTTCCAGTTGGTGTAAGGT ( <i>LSAMP</i> )	66
LSAMP-NORE1A	Forward	TTCTCTGGAATACAGCCTCCG ( <i>LSAMP</i> )	67
LSAMP-NORE1A	Reverse	GCGTGTTGTAGCTGTCGATC ( <i>NORE1A</i> )	68
NORE1B-LSAMP	Forward	GCAGCATGAGCAGTGGGTAC ( <i>NORE1B</i> )	69
NORE1B-LSAMP	Reverse	TTTGCCTGACTGCTCCCTG ( <i>LSAMP</i> )	70
<b><i>For mutation analyses</i></b>			
<b><i>NORE1 gene</i></b>			
NORE1A Exon 1	Forward	TCCTTCCTGCCACTCCGACTC	71
NORE1A Exon 1	Reverse	TCCCAAGAACTCACAACAAAACC	72
NORE1A Exon 1	Sequencing		73
NORE1A Exon 1	Forward	TCCTTCCTGCCACTCCGACT	74
NORE1A Exon 1	Sequencing		75
NORE1A Exon 1	Reverse	TCCTCGCGCCTCTGTGTCCC	76
NORE1A Exon 2	Forward	TCCAAGGTTATTTCTCTGGGTG	77
NORE1A Exon 2	Reverse	GAGTTCTCTGTGTCACTTCCCC	78
NORE1A Exon 3	Forward	CTGGATGCTCACTTCTTGGTTAG	79
NORE1A Exon 3	Reverse	CAGAATTCAGAGTGAGGGCAG	80
NORE1A Exon 4	Forward	AGAACTCAAGGAGACAGGTGGG	81
NORE1A Exon 4	Reverse	AGATCTGAACACCACATGGGC	82

Target	Direction	Sequence (5'-3')	SEQ ID NO:
<i>NORE1A</i> Exon 5	Forward	CACCTCTGCATTTCCAATCCTT	80
<i>NORE1A</i> Exon 5	Reverse	GTGGCTCCACCTATGTGAG	81
<i>NORE1A</i> Exon 6	Forward	CAGGGTCTCTCAGGTCGTGTCA	82
<i>NORE1A</i> Exon 6	Reverse	CCCCATGCAAACACTTGTC	83
<i>NORE1B</i> Exon1	Forward	CCCGCTGAAAGAAACGCAGG	84
<i>NORE1B</i> Exon1	Reverse	ATGCTCAGCCCTCAGGGCAA	85
<b><i>LSAMP</i> gene</b>			
<i>LSAMP</i> Exon1	Forward	AGTGGAAAGGACCATAAACTGGC	86
<i>LSAMP</i> Exon1	Reverse	TGGAGTTCAAGGAGATCAGACAC	87
<i>LSAMP</i> Exon2	Forward	ATGACATCCATCCACTGGATG	88
<i>LSAMP</i> Exon2	Reverse	TGCAACTCCACCTCTTCTTA	89
<i>LSAMP</i> Exon3	Forward	AGATGGCAAGCATGGGTCTTA	90
<i>LSAMP</i> Exon3	Reverse	TCAGCAGAATTCCAGGAGCA	91
<i>LSAMP</i> Exon4	Forward	CTGCTTCTGTGGAATCTGATGTC	92
<i>LSAMP</i> Exon4	Reverse	CAAAGACCAAGTCCTGCCCTT	93
<i>LSAMP</i> Exon5	Forward	CTCCCTTCCTGCCTCTCTCTAA	94
<i>LSAMP</i> Exon5	Reverse	GCTTAAGAGCTACAGGCCCC	95
<i>LSAMP</i> Exon6	Forward	TCCTTTTCCTCCAGTGTGAGG	96
<i>LSAMP</i> Exon6	Reverse	TGCTATGCACAGGAGTTGAGAA	97
<i>LSAMP</i> Exon7	Forward	CTTCTTGGGCTGCACATAAGTG	98
<i>LSAMP</i> Exon7	Reverse	ACGGTCTCCCCATCTCTCT	99
<b><i>VHL</i> gene</b>			
<i>VHL</i> Exon1	Forward	TGTA AACGACGGCCAGT CGAAGAGTACGGCCCTGAAGA AGAC	100
<i>VHL</i> Exon1	Reverse	CAGGAAACAGCTATGACCCAGTACCCTGGATGTGTCCTG CCTC	101
<i>VHL</i> Exon2	Forward	TGTA AACGACGGCCAGTAGACGAGGTTTCACCACGTTA GC	102
<i>VHL</i> Exon2	Reverse	CAGGAAACAGCTATGACCGTCCTCTATCCTGTACTTACC AC	103
<i>VHL</i> Exon3	Forward	TGTA AACGACGGCCAGTCTGAGACCCTAGTCTGCCACT GAGGAT	104
<i>VHL</i> Exon3	Reverse	CAGGAAACAGCTATGACCCAAAAGCTGAGATGAAACAGT GTAAGT	105

The cloning of the breakpoints led to the identification of two breakpoint-spanning genes, *NORE1* on 1q32.1 and *LSAMP* on 3q13.3 (Figure 2B). To investigate whether fusion proteins resulting from the chromosome translocation are involved in tumorigenesis of CC-RCC, Northern blot analysis and RT-PCR were carried out to detect any fusion transcript of *NORE1* and *LSAMP* (see Table A in supplemental data). No detectable fusion transcripts were found in the FRCC3 and FRCC5 cell lines from two patients in the t(1;3) family. The possible sequence combination from *NORE1* and *LSAMP* were also tested. Since *NORE1* lies in the positive DNA strand and *LSAMP* in the reverse strand, there is little likelihood for them to form any *NORE1-LSAMP* or *LSAMP-NORE1* fusion proteins.

Given the association between chromosome 3 translocations and CC-RCC susceptibility (van Kessel *et al.*, 1999; Bodmer *et al.*, 2002c), the gene *LSAMP* was investigated. *LSAMP* is composed of seven exons and is disrupted in intron 2 by the breakpoint (Figure 2B). To elucidate whether genetic changes in *LSAMP* play a role in CC-RCC, *LSAMP* mutation analysis was performed in 9 CC-RCC cell lines and in 53 sporadic and 4 familial tumors. No *LSAMP* mutation was detected. However, epigenetic silencing in association with hypermethylation, the most common form of inactivation for many tumor suppressor genes (Jones *et al.*, 2002), could still occur. First, RT-PCR analysis showed that *LSAMP* was down-regulated in all nine RCC cell lines (Figure 3A). Furthermore, the *LSAMP* promoter was methylated in 7/9 CC-RCC cell lines (78%), 14/53 sporadic CC-RCCs (26%), and all 4 familial CC-RCCs tumors from the t(1;3) family (Figure 3B). In association with the promoter-methylation status, *LSAMP* expression in ten examined tumors with *LSAMP*-promoter methylation was also down-regulated (Figure 3A). Of the *LSAMP*-promoter-methylated cell lines and tumors, all presented complete methylation except two cell lines and one sporadic tumor. Furthermore, in the four familial tumors (FT1 to FT4), one *LSAMP* allele was breakpoint-disrupted followed by the loss of the der(3) chromosome shown in our previous study (Kanayama *et al.*, 2001), and the other copy was hypermethylated (Figure 3B), implying *LSAMP* may undergo bi-allelic inactivation. These observations suggest that *LSAMP* is involved in CC-RCC, though further functional studies are needed to elucidate its mechanism.

The 1q32.1 breakpoint-disrupted gene, *NORE1*, also appeared to be an excellent candidate CC-RCC suppressor gene. *NORE1* undergoes alternative splicing, resulting in two isoforms, *NORE1A* and *NORE1B*. The breakpoint disrupted both *NORE1A* and *NORE1B* (Figure 2B). *NORE1* is homologous to a family of RAS binding proteins, including RASSF1,

rat Maxp1, and murine Nore1 (Vavvas *et al.*, 1998; Dammann *et al.*, 2000; Vos *et al.*, 2000; Ortiz-Vega *et al.*, 2002; Tommasi *et al.*, 2002) that have been proposed to be effectors for the small GTPase. Maxp1, Nore1 and RASSF1 have been shown to induce apoptosis (Vos *et al.*, 2000; Khokhlatchev *et al.*, 2002). Other studies, however, have shown that Nore1 family members are cytostatic and modulate cyclinD1 levels, thereby influencing the activity of cell cycle-dependent kinases (Khokhlatchev *et al.*, 2002). *RASSF1* maps to 3p21, a region of frequent LOH in CC-RCC (van den Berg *et al.*, 1997; Dammann *et al.*, 2000), and this gene has recently been shown to be epigenetically inactivated in kidney cancer (Dreijerink *et al.*, 2001; Morrissey *et al.*, 2001; Yoon *et al.*, 2001). Thus, the inventors proceeded to investigate *NORE1* as a candidate RCC suppressor.

Mutation screening and methylation analysis were performed on *NORE1* in all the RCC cell lines and tumors. Two alterations, GTG(Val189)>ATG(Met189) and CGG(Arg248)>CAG(Gln248), were identified (see Figure 6). The former was present in 5% of the 100 tested normal subjects, whereas the latter was not found in any of them. As both were also present in the matched normal kidney tissues, it is likely that they represent polymorphisms. The inventors then perceived that *NORE1A* expression was also down-regulated in the 9 RCC cell lines, and the *NORE1A* promoter was methylated in 6/9 RCC cell lines and 17/53 (32%) sporadic RCC tumors (Figure 3A and 3C), whereas methylation in the *NORE1B* promoter was detected only in RCC cell lines A-498 and A-704. *NORE1A* expression in examined 10 of the 17 affected tumors was also down-regulated (Figure 3A). Two normal kidney control samples (N3 and N44) also showed *NORE1A* promoter methylation at lower extents compared with their matched tumors (3T and 44T), probably due to contamination from the tumor tissues. Interestingly, *NORE1A*-promoter methylation does not overlap with *LSAMP*-promoter methylation except in four tumors. These results suggest that *NORE1A* is also associated with sporadic CC-RCC. Yet, unlike the methylation situation in *LSAMP*, only 1/4 hereditary tumors showed even slight *NORE1A* promoter methylation, indicating one wild-type allele of *NORE1A* still exists in these hereditary tumors. Whether *NORE1A* undergoes haploinsufficiency in tumorigenesis remains undetermined.

In addition, 7/14 tumors (50%) with *LSAMP*-promoter methylation showed loss of heterozygosity (LOH) of the *LSAMP* locus. However, LOH was also observed in 17/39 tumors (44%) without *LSAMP*-promoter methylation. Similar LOH results were obtained on *NORE1A*

(methylated, 5/17 [29%]; unmethylated, 8/36, [22%]), indicating that the LOH may be correlated with CC-RCC tumorigenesis, but is not methylation-dependent.

Promoter methylation in both *LSAMP* and *NORE1A* may also be linked to other types of cancers. *NORE1A*-promoter methylation has recently been detected in cancer cell lines and in 24% NSCLC (Hesson *et al.*, 2003). Here the inventors found that the *LSAMP* promoter was methylated in 5/19 (26%) colorectal cancers.

The exact role of these genes in tumorigenesis is unclear. Without wishing to be bound to any particular mechanism, potential roles for these genes are discussed below. In the familial cases, the underlying mechanism appears to be the three-step model of chromosome 3 translocation-related hereditary CC-RCC tumorigenesis (Bodmer *et al.*, 1998; Kanayama *et al.*, 2001; Bodmer *et al.*, 2002c). Considering the complexity of the multistep process in tumorigenesis, the possibility exists that the breakpoint-disrupted genes, especially *LSAMP*, may contribute to the occurrence of familial tumors by acting as components in the three-step model of tumorigenesis of hereditary CC-RCC. The inventors have previously demonstrated that four examined familial CC-RCC tumors lost the der(3) chromosome and two of them carry *VHL* mutations, supporting the three-step model of tumorigenesis (Kanayama *et al.*, 2001). Here, the inventors supplement this model with our *LSAMP* and *NORE1A* data. The constitutional translocation t(1q;3q) and disruption of a copy each of *LSAMP* and *NORE1*, as the first set of steps of tumorigenesis, act as the predisposing factors in development of CC-RCC. The translocation also results in the increased susceptibility to somatic loss of the chromosome der(3). The following non-disjunctional loss of der(3) deletes a copy each of the RCC-related genes in chromosome 3 (e.g., *VHL*, *RASSF1A*), which further increases the predisposition to CC-RCC. This second set of steps will accelerate the transformation process and cellular growth, leading to the third set of steps involving either the inactivation of the other *VHL* allele (e.g. somatic mutation) or the genetic/epigenetic alternations in other CC-RCC-related genes including *LSAMP* in the remaining copy of chromosome 3. These factors may act synergistically and finally lead to the occurrence of CC-RCC.

Epigenetic inactivation of these genes can be reversed by demethylation treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR). The demethylation treatment resulted in significantly increased expression of *LSAMP* and *NORE1* in eight cell lines (Figure 3A), indicating that repression is at least in part mediated by methylation.



Finally, to further evaluate the role of *LSAMP* and *NORE1* as tumor suppressor candidates in cancer, enhanced green fluorescent protein *EGFP-LSAMP*, *-NORE1A*, and *-Nore1* expression plasmids were microinjected or transfected into two RCC cell lines, A-498 and/or Caki-1, in which the *LSAMP* and *NORE1A* promoters were methylated, cells were then counted at indicated times, and were monitored for cell number and/or proliferation. Alternatively, cells were monitored by epi-fluorescence/phase-contrast microscopy to evaluate proliferation, fluorescent protein expression, or apoptosis. While cells expressing EGFP continued to proliferate at rates similar to those of uninjected neighbors, cells expressing EGFP-LSAMP, -NORE1A and -Nore1 failed to divide (Figure 4B). There was no evidence of apoptosis in any of the experiments. This growth inhibition role was also demonstrated in 293-T cells stably transformed with an inducible *Nore1* gene by lipid-mediated transfection (see Figure 7C).

The inventors also observed that EGFP-LSAMP seemed to be cytoplasmic, and EGFP-NORE1A appeared in both cytosol and nucleus. EGFP-Nore1 was predominantly nuclear and tended to occupy discrete puncta within the nucleus (Figure 4A). This was observed in both formaldehyde-fixed and living cells; thus, the localization was unlikely to be due to a fixation artifact. Furthermore, the nuclear localization of EGFP-Nore1 was also confirmed in the transfected Caki-1 RCC cell line and in the 293-T cells by nuclear fractionation (see Figures 7Aa and 7B).

These observations are consistent with a growth suppression role for LSAMP, NORE1A, and NORE1. Also, despite the presence of a putative Ras-association region, the results suggest that this nuclear Nore1 protein may not be a *bona fide* Ras effector, whose family members tend to be lipid-modified, membrane-bound, positive regulators of cell proliferation. Further investigation into its role in growth regulation (potentially through the regulation of cyclin D1 and G1/S progression) and its role in the nucleus are desirable.

Based on these data, LSAMP, and NORE1A (a homolog of 3p21-tumor suppressor RASSF1A), represent new tumor suppressor candidates, and presumably act as components in the multistep process of CC-RCC tumorigenesis. Inactivation or reduced expression of both LSAMP and NORE1A also appears to be involved in the occurrence of other types of tumors. Further studies of these genes may lead to the elucidation of novel mechanisms of tumorigenesis.

**GenBank accession numbers and Sequences of NORE1A, LSAMP, etc.****NORE1A: GenBank Accession No. NM\_031437**

Nucleic Acid: SEQ ID NO: 120 (coding: 64-1236); Amino acid: SEQ ID NO:121,

```

5      1 cgggagtagc gcagtcgcca aagccgcgcg tgccaaagct gccgccacta gccgggcatg
      61 gccatggcgt ccccggccat cgggcagcgc cgtaccgcg tactcttggg ccccgagccg
      121 ccgcgcctatc tacagagcct gagcggcccc gagctaccgc cgccgcccc cgcacgggtcc
      181 tcgcgcctct gtgtcccggc gccctctccc actgcgcccg gggcgcgcgga gggcgcgagc
      241 gcccgagggg ctgcccgggg gaacctggag ccccgcccc gggcctccc acccgctcgc
      301 ccgctccggc ctggctctgca gcagagactg cggcgcgcg cggagcgcc ccgacccgc
10     361 gacgtgcgga gcatcttcga gcagccgcag gatccagag tcccgcgga gcgagggcag
      421 gggcactgct tcgcccagtt ggtgctgccc ggcggcccc gctggtgtga cctgtgcgga
      481 cgagaggtgc tgcggcaggc gctgcgctgc actaactgta aattcacctg tccccagaa
      541 tgccgcagcc tgatccagtt ggactgcagt cagcaggagg gtttatccc ggacagaccc
      601 tctccagaaa gcaccctcac cgtgaccttc agccagaatg tctgtaaacc tgtggaggag
15     661 acacagcgcc cgcccacact gcaggagatc aagcagaaga tcgacagcta caacacgcga
      721 gagaagaact gcctgggcat gaaactgagt gaagacggca cctacacggg tttcatcaaa
      781 gtgcatctga aactccggcg gcctgtgacg gtgctgctg ggatccggcc cagttccatc
      841 tatgatgcca tcaaggaggt gaacctggcg gctaccacgg acaagcgga atccttctac
      901 ctgcccctag atgccatcaa gcagctgcac atcagcagca ccaccacgt cagtgggtc
20     961 atccaggggc tgctcaagaa gttcatggtt gtggacaatc ccagaagtt tgcacttttt
      1021 aagcggatac acaaggacgg acaagtgtct tccagaaac tctccattgc tgaccgccc
      1081 ctctacctgc gcctgcttgc tgggcctgac acggagggtc tcagctttgt gctaaaggag
      1141 aatgaaactg gagaggtaga gtgggatgcc ttctccatcc ctgaacttca gaacttcctc
      1201 tctcctgggt gcattcagat ttatttgtat tattaattat tattttgcaa cagacacttt
25     1261 ttctcaggac atctctggca ggtgcatttg tgctgccc gcagttccag ctgtggcaaa
      1321 agtctcttcc atggacaagt gtttgcacga ggttccagct gtgcccgcg cagcgctgtg
      1381 cccaccaca gattctgcca aggatcagaa ctcatgtgaa acaaacagct gacgtcctc
      1441 ctcgatctgc aagcctttca ccaacaaat agttgcctct ctctcacca aactggaacc
      1501 tcacaccagc cggcaaagga aggaagaaag gttttagagc tgtgtgttct ttctctggca
30     1561 ttgattcctc tttagattct cttacttgcc acgtacagga ccattattta tgagtgaana
      1621 gttgtagcac attccttttg caggtctgag ctaagccct gaaagcaggg taatgctcat
      1681 aaaaggactg ttcccgcggc ccaagggtgc ctgttgttca cacttaaggg aagtttataa
      1741 agctactggc ccagatgct cagggttaagg agcaccaaaag ctgaggctgg ctgagagatc
      1801 tccagagaag ctgcagcctg cctggccct ggctctggcc ctggcccaca ttgcacattg
35     1861 aaacccaaag gcataatatc gcgtatgtgt ggtacttagt cacatctttg tcaacaaact
      1921 gttcgttttt aagttacaaa tttgaattta atgttgtcat catcgtcatg tgtttcccca
      1981 aagggaagcc agtcattgac catttaaaaa gtctcctgct aagtatggaa atcagacagt
      2041 aagagaaagc caaaaagcaa tgcagagaaa ggtgtccaag ctgtcttcag ccttcccag
      2101 ctaaagagca gaggaggggc tgggtacttt gggttcccca tcggcctcca gcactgcctc
40     2161 cctcctccca ctgcgactct gggatctcca ggtgctgccc aaggagtgtc cttgattaca
      2221 gagaggggag cctccaattc ggccaacttg gagtcctttc tgttttgaag catgggcccag
      2281 acccggcact gcgctcggag agccggtggg cctggcctcc ccgtcgacct cagtgccttt
      2341 ttgttttcag agagaaatag gactagggcg agtttgctg aagctctgct gctggcttct
      2401 cctgccagga agtgaacaat ggcggcggtg tgggagacaa ggccaggaga gcccgcttc
45     2461 agtatgggtt gagggtcaca gacctccct ccatctgggt gctgagttt tgactccaat
      2521 cagtataacc agaccacatt gacagggagg atcaaatcc tgacttacat ttgactggc
      2581 ttcttgttta ggctgaatcc taaaataaat tagtcaaaaa attccaacaa gtagccagga
      2641 ctgcagagac actccagtgc agagggagaa ggacttgtaa ttttcaaagc agggctgggt
      2701 ttccaaccca gcctctgaga aaccatttct ttgtatcct ctgccttccc aagtccctct
50     2761 tgggtcggtt caagcccaag cttgttcgtg tagcttcaga agttccctct ctgaccagg
      2821 ctgagtccat actgcccctg atcccagaag gaatgctgac cctcgtcgt atgaactgtg
      2881 catagtctcc agagcttcaa aggaacaca agctcgcaac tctaagattt ttttaacca
      2941 caaaaacctt ggtaggcat ctcatgctca gccttatcac ttccctccct tttagaaactc
      3001 tctccctgct gtatatataa gggagcaggt ggagagtcac ttctctcgt cctgcatgtc
55     3061 tctaacatta atagaaggca tggctcctgc tgcaaccgct gtgaatgctg ctgagaacct
      3121 cctctatgg ggatggctat tttatttttg agaaggaaaa aaaaagtcac gtatatatac

```

3181 acataaagggc atatatgctat atataaagag ataaggggtgt ttatgaaatg agaaaattat  
 3241 tggacaattc agactttact aaagcacagt tagaccaag gcctatgctg aggtctaaac  
 3301 ctctgaaaaa agtatagtat cgagtaccgc tccctccca gaggtgggag taactgctgg  
 3361 tagtgccctc tttgggtgtg ttgctcagtg tgtaagtgtt tgtttccagg atattttctt  
 5 3421 ttttaaatgtc tttcttataat gggtttttaa aaaaagtaat aaaagcctgt tgcaaaaatg  
 3481 aaaaaaaaaa aaaaaaaa\

MASPAIGQRP YPLLLDPEPP RYLQSLSGPE LPPPPDRSS RLCVPAPLST APGAREGRSA  
 10 RRAARGNLEP PPRASRPAP LRPGLQQLR RRPAPRPRD VRSIFEQPD PRVPAEREGE  
 HCFAELVLP GPGWCDLCGR EVLRQALRCT NCKFTCHPEC RSLIQLDCSQ QEGLSRDRPS  
 PESTLTVTF QNVCKPVEET QRPPTLQEI KIDSNTRE KNCLGMKLSE DGTGTGFIKV  
 HLKLRPVTV PAGIRPQSIY DAIKEVNLAA TTDKRTSFYL PLDAIKQLHI SSTTTVSEVI  
 QGLLKKFMV DNPQKFALFK RIHKDQVLF QKLSIADRPL YLRLLAGPDT EVLSFVLKEN  
 15 ETGEVEWDAF SIPELQNFLS SWCIQIYLY

**NORE1B: GenBank Accession No. AF445801**

Nucleic acid - SEQ ID NO: 122 (coding: 411-1208); Amino acid: SEQ ID NO:123

1 gaactgcttt acgcgagggg caaggaaagg cgccggaggc gggggagggtg cggagatggc  
 20 61 gctctgcacg gcggcggagg gagggcgctg gcgcggggga cagaaaaccg cagagcccg  
 121 acgagtcagg gagtgaggcg cgagccgggc gcccggggct ctgcaggcgc aggcggcgcg  
 181 gggacaggag caggttaccg ggccgcccga gcgctgcac cccgctgaaa aaaacgcagg  
 241 cggcccgccg gctttgcctg gtccgatacc cgaccagctc ccggctcggg gctcagagct  
 301 aggggcttac gccaaagcga gcccggggag ggggtgccac ctccctccgc cgcattccaa  
 361 gcccgccccc cttgatgcgc tggcgccctc ggccgggaac tccggggtag atgaccgtgg  
 25 421 acagcagcat gagcagtggg tactgcagcc tggacgaggg actggaagac tgctttctca  
 481 ctgctaagac tacctttttc agaaatgcgc agagcaaaca tctttcaaag aatgtctgta  
 541 aacctgtgga ggagacacag cgcgcgccc cactgcaggg gatcaagcag aagatcgaca  
 601 gctacaacac gcgagagaag aactgcctgg gcatgaaact gagtgaagac ggcacctaca  
 661 cgggtttcat caaagtgcac ctgaaactcc ggcggcctgt gacggtgcct gctgggatcc  
 30 721 ggccccagtc catctatgat gccatcaagg aggtgaacct ggcggtacc acggacaagc  
 781 ggacatcctt ctacctgcc ctgatgcc tcaagcagct gcacatcagc agcaccacca  
 841 ccgtcagtag ggtcatccag gggctgctca agaagttcat ggttgtagg aatccccaga  
 901 agtttgact ttttaagcgg atacacaagg acggacaagt gctcttccag aaactctoca  
 961 ttgctgaccg cccctctac ctgcgcctgc ttgctgggcc tgacacggag gtcctcagct  
 35 1021 ttgtgctaaa ggagaatgaa actggagagg tagagtggga tgccttctcc atccctgaac  
 1081 ttcagaactt cctaacaatc ctggaaaaag aggagcagga caaatccaa caagtgcaaa  
 1141 agaagtatga caagtttagg cagaaactgg agggagcctt aagagaatcc cagggcaaac  
 1201 ctgggtaacc agtccctgctt cctctcctcc tgggtgcatt agatttattt gtattattaa  
 1261 ttattatttt gcaacagaca ctttttctca ggacatctct ggcagggtgca tttgtgcctg  
 40 1321 cccagcagtt ccagctgtgg caaaagtctc tccatggac aagtgtttgc acgggggttc  
 1381 agctgtgccc gccccagggc tgtgccccac cacagattct gccaaggatc agaactcatg  
 1441 tgaacaaaa agctgacgtc ctctctcgat ctgcaagcct ttcaccaacc aaatagttgc  
 1501 ctctctcgtc accaaactgg aacctcacac cagccggcaa aggaagggaag aaaggtttta  
 1561 gagctgtgtg ttctttctct ggctttgatt cttctttgag ttctcttact tgccacgtac  
 45 1621 aggaccatta tttatgagtg aaaagttgta gcacattcct tttgcaggtc tgagctaaac  
 1681 cctgaaagc agggtaatgc tcataaaagg actgttcccg cggcccaag gtgcctgttg  
 1741 ttcacactta aggggaagtt ataaagctac tggccccaga tgctcagggt aaggagcacc  
 1801 aaagctgagg ctggctcaga gatctccaga gaagctgcag cctgcctctg cctggctct  
 1861 ggccctggcc cacattgcac atggaaaccc aaaggcatat atctgcgtat gtgtggtact  
 50 1921 tagtcacatc tttgtcaaca aactgttcgt ttttaagtta caaatttgaa tttaatgttg  
 1981 tcatcatcgt catgtgtttc cccaaaggga agccagtcac tgaccattta aaaagtctcc  
 2041 tgctaaagt ggaatcaga cagtaagaga aagccaaaaa gcaatgcaga gaaaggtgtc  
 2101 caagctgtct tcagccttcc ccagctaaag agcagaggag ggcctgggct acttgggttc  
 2161 cccatcggcc tccagcactg cctccctcct cccactgoga ctctgggatc tccaggtgct  
 55 2221 gcccaaggag ttgccttgat tacagagagg ggagcctcca attcgcccaa cttggagtcc  
 2281 tttctgtttt gaagcatggg ccagaccggg cactgcgctc ggagagccgg tgggcctggc

2341 ctccccgctg acctcagtg ctttttgttt tcagagagaa ataggagtag ggcgagtttg  
 2401 cctgaagctc tgotgctggc ttctcctgcc aggaagtga caatggcggc ggtgtgggag  
 2461 acaaggccag gagagccgc gttcagtag ggttgagggt cacagacct cctccatct  
 2521 gggtgccctg gttttgactc caatcagtg taccagacca cattgacagg gaggatcaaa  
 5 2581 ttcttgactt acatttgac tggcttcttg tttaggctga atcctaaaat aaattagtca  
 2641 aaaaattcca acaagtagcc aggactgcag agacactcca gtgcagaggg agaaggactt  
 2701 gtaattttca aagcagggtt ggttttccaa cccagcctct gagaaacct ttctttgcta  
 2761 tcctctgcct tcccaagtcc ctcttgggtc ggttcaagcc caagcttggt cgtgtagctt  
 10 2821 cagaagttcc ctctccgacc caggctgagt ccatactgcc cctgatcca gaaggaatgc  
 2881 tgacccctcg tcgtatgaac tgtgcatagt ctccagagct tcaaaggcaa cacaagctcg  
 2941 caactctaag atttttttta accacaaaaa ccctgggttag ccatctcatg ctcagcctta  
 3001 tcacttccct ccctttttaga aaactctctc cctgctgtat attaaagga gcaggtggag  
 3061 agtcattttc ctctgtcttg catgtctcta acattaatag aaggcatggc tctgtctgca  
 3121 accgtgtgta atgctgctga gaacctccct ctatggggat ggctatttta tttttgaaa  
 15 3181 ggaaaaaaa agtcatgtat atatacacat aaaggcatat agctatataa aaagagataa  
 3241 ggggtgtttat gaaatgagaa aattattgga caattcagac ttactaaag cacagttaga  
 3301 cccaaggcct atgctgaggt ctaaacctct gaaaaaagta tagtatcgag taccggtcc  
 3361 ctcccagagg tgggagtaac tgctggtagt gccttctttg gttgtgttg cagtgtgta  
 3421 agtgtttgtt tccaggatat tttcttttta aatgtctttc ttatatgggt ttaaaaaaa  
 20 3481 agtaataaaa gcctgttgc

25 MTVDSSMSSG YCSLDEELED CFFTAKTTF RNAQSKHLSK NVCKPVEETQ RPPTLQEIQK  
 KIDSYNTREK NCLGMKLSLSED GTYTGFIVH LKLRRPVTV AGIRPQSIYD AIKEVNLAAT  
 TDKRTSFYLP LDAIKQLHIS STTTVSEVIQ GLLKKFMVVD NPQKFALFKR IHKDGQVLFQ  
 KLSIADRPLY LRLLAGPDTE VLSFVLKENE TGEVEWDAFS IPELQNFLT ILEKEEQDKIQ  
 QVQKKYDKFR QKLEELRES QGKPG

LSAMP NM\_002338 cDNA

Nucleic acid: SEQ ID NO: 124 (coding: 501-1517); Amino acid SEQ ID NO:125

30 1 ggggagagag gctctgggtt gctgctgctt ctgctgctgc tgcctgctgtg tggctgtttc  
 61 tgtacactca ctggcaggct tgggtgccgc tccctcgccc gcccgccgc cagcctggga  
 121 aagtgggtta cagagcgaag gagctcagct cagacactgg cagaggagca tccagtcaca  
 181 gagagaccaa acaagaacc ttctcttttg ttctctcttc agctcttcca gaggtcttgc  
 241 tatttgcaact ctctcttttg aaattgtgtt gcttttactt ttcaccttc tgcctgggtt  
 35 301 ttatgagggc tttgttaagt cttagagggga aaagagactg agcgagggaa agagagaggg  
 361 aaagtggaaa ggaccataaa ctggcaaagc ccgctctgct ctcgctgtgg atgaaagccc  
 421 cgtgttggtg aagcctctct tcgagagcag cgcgcacccc tccagagcac cccgaggacc  
 481 cgcacctcgg cgtggccacc atggtcagga gagttcagcc ggatcggaaa cagttgccac  
 541 tggctctact gagattgctc tgcctctctc ccacaggact gcctgttgc agcgtggatt  
 40 601 ttaaccgagg caggacaac atcacctga ggcaggggga cacagccatc ctgaggtgct  
 661 ttgtagaaga caagaactca aaggtggcct ggttgaaccg ttctggcatc atttttgctg  
 721 gacatgacaa gtggtctctg gacccacggg ttgagctgga gaaacgccat tctctggaat  
 781 acagcctccg aatccagaag gtggatgtct atgatgaggg ttctacact tgcctagttc  
 841 agacacagca tgagcccaag acctcccaag tttacttgat cgtacaagtc ccaccaaaaga  
 45 901 tctccaatat ctctcggat gtcactgtga atgagggcag caactgtact ctggtctgca  
 961 tggccaatgg ccgtcctgaa cctgttatca cctggagaca ccttacacca actggaaggg  
 1021 aatttgagg agaagaagaa tatctggaga tccttggcat caccagggag cagtcaggca  
 1081 aatatgagtg caaagctgcc aacgaggtct cctcggcgga tgtcaaacaa gtcaaggtca  
 1141 ctgtgaacta tctctccact atcacagaat ccaagagcaa tgaagccacc acaggacgac  
 50 1201 aagcttcaact caaatgtgag gcctcggcag tgcttgcacc tgactttgag tggtagcggg  
 1261 atgacactag gataaatagt gccaatggcc ttgagattaa gagcacggag ggccagctct  
 1321 cctgacggg gaccaacgct actgaggagc actacggcaa ctacacctgt gtggctgcca  
 1381 acaagctggg ggtcaccaat gccagcctag tccttttcag acctgggtcg gtgagaggaa  
 1441 taaatggatc catcagctctg gccgtaccac tgtggctgct ggcagcatct ctgctctgcc  
 55 1501 ttctcagcaa atgttaatag aataaaaaat taaaaataaa aaaaaaaaaa aaaaaaaaaa  
 1561 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

1621 aaaaaaaaaa aaaaaaaaaa

MVRVQPDRL QLPLVLLRLL CLLPTGLPVR SVDENRGTDN ITVRQGDIAI LRCVVEDKNS  
 KVAWLNRSGI IFAGHDKWSL DPRVELEKRH SLEYSRLRIK VDVYDEGSYT CSVQTQHEPK  
 5 TSQVYLIVQV PPKISNISSD VTVNEGSNT LVCMANRPE PVITWRHLTP TGREFESEEE  
 YLEILGITRE QSGKYECKAA NEVSSADVKQ VKVTVNYPPT ITESKSNEAT TGRQASLKCE  
 ASAVPAPDFE WYRDDTRINS ANGLEIKSTE GQSSLTVTNV TEEHYGNYTC VAANKLGVTN  
 ASLVLFPRGS VRGINGSISL AVPLWLLAAS LLCL

10 ASSF1A, GenBank Accession No. AF132675;

Nucleic acid: SEQ ID NO: 126 (coding: 39-1061); Amino acid SEQ ID NO:127

1 agcgcccaaa gccagcgaag caggggcccc accggggccat gtcggggggag cctgagctca  
 61 ttgagctgcg ggagctggca cccgctgggc gcgctgggaa gggccgcacc cggctggagc  
 121 gtgccaacgc gctgcgcac cgcgggggca cgcgctgcaa cccacacagg cagctggctc  
 15 181 ctggccgttg ccaccgcttc cagcccgagg gggccggcac gcacacgttg tgcgacctct  
 241 gtggcgactt catctggggc gtcgtgcgca aaggcctgca gtgcgcgat tgcagttca  
 301 cctgccacta ccgctgcgcg gcgctcgtct gcctggactg ttgcgggccc cgggacctgg  
 361 gctgggaacc cgcggtggag cgggacacga acgtggacga gcctgtggag tgggagacac  
 421 ctgacctttc tcaagctgag attgagcaga agatcaagga gtacaatgcc cagatcaaca  
 20 481 gcaacctctt catgagcttg aacaaggacg gttcttacac aggtctcatc aaggttcagc  
 541 tgaagctggt gcgccctgtc tctgtgccct ccagcaagaa gccacctctc ttgcaggatg  
 601 cccggcgggg ccaggacagg ggcacaagtg tcaggcgccg cacttccttt tacctgcccc  
 661 aggatgctgt caagcaccta catgtgctgt cagcacaag ggcacgtgaa gtcattgagg  
 721 cctgctgcg aaagtctctg gtggtagatg acccccgcaa gtttgactc tttgagcgcg  
 25 781 ctgagcgtca cggccaagtg tacttgcgga agctgttgga tgatgagcag cccctgcggc  
 841 tgcggctcct ggcaggggcc agtgacaagg ccctgagctt tgcctgaag gaaaatgact  
 901 ctggggaggt gaactgggac gccttcagca tgctgaact acataacttc ctacgtatcc  
 961 tgcagcgagg ggaggaggag cactccgcgc agatcctgca gaagtactcc tattgcggcc  
 1021 agaagatcca agaggccctg cagcctgcgc cccttgggtg acctcttgta ccccgagggtg  
 30 1081 gaaggcagac agcaggcagc gccaaagtgc tgccgtgtga gtgtgacagg gccagtgagg  
 1141 cctgtggaat gagtgtgcat ggaggccctc ctgtgctggg ggaatgagcc cagagaacag  
 1201 cgaagtagct tgctccctgt gtccacctgt ggggtgtagc aggtatggct ctgacacctc  
 1261 ctgacctcat tactgggcct tagtgggcca gggctgccc gagagctgc tccaggcctg  
 1321 cagcaggagt ggtgcagaca gaagtctcct caatttttgt ctcagaagtg aaaatcttgg  
 35 1381 agacctgca aacagaacag ggtcatgttt gcagggggtga cggccctcat ctatgaggaa  
 1441 aggttttggg tcttgaatgt ggtctcagga tatccttatc agagctaagg gtgggtgctc  
 1501 agaataaggc aggcattgag gaagagtctt ggtttctctc tacagtcca actcctcaca  
 1561 caccctgagg tcagggagtg ctggctcaca gtacagcatg tgccttaatg ctccatatga  
 1621 ggaggatgtc cctgggcccag ggtctgtgtg aatgtgggca ctggcccagg ttcataacctt  
 40 1681 atttgctaata caaagccagg gtctctcctc caggtgtttt ttatgaagtg cgtgaatgta  
 1741 tgtaatgtgt ggtggcctca gctgaatgcc tcctgtgggg aaaggggttg gggtagagtg  
 1801 catcatcagg gcctggggcc tgagagaatt ggctcaataa agatttcaag atccaaaaaa  
 1861 aaaaaaaaaa aaa

45 MSGEPETIEL RELAPAGRAG KGRTRLERAN ALRIARGTAC NPTRQLVPGR GHRFQAPGPA  
 THTWCDLGGD FIWGVVRKGL QCAHCKFTCH YRCRALVCLD CCGPRDLGWE PAVERDTNVD  
 EPVEWETPDL SQAEIEQKIK EYNAQINSNL FMSLNKDGSY TGFIKVQLKL VRPVSVPSSK  
 KPPSLQDARR GPGRGTSVRR RTSFYLPKDA VKHLHLVLSRT RAREVIEALL RKFLVDDPR  
 50 KFALFERAER HGQVYLRKLL DDEQPLRLRL LAGPSDKALS FVLKENDSGE VNWDASFMSPE  
 LHNFLRLQR EEEHLRQIL QKYSYCRQKI QEALHACPLG

Norel, AF053959;

Nucleic acid: SEQ ID NO: 128 (coding: 31-1272); Amin0 Acid: SEQ ID NO: 129

	1	gtagctgccc	cgctgactga	ggccttggcc	atggcttccc	cggccatcgg	gcaacgtccc
5	61	taccgcctgc	tcctagatcc	cgagccggcc	cggatatctgc	agagtctggg	tgccaccgag
	121	ccgccacctc	ccgcccgggc	gcgccgctgc	atccccacgg	ccctgatccc	cgccggccggg
	181	gcgtcagagg	atcgcggtgg	caggaggagt	ggccggaggg	accccgaaac	cacgccccga
	241	gactgccgac	acgctcgccc	tgtccggccc	ggctctgcagc	cgagactgcg	gctgcgacct
	301	gggtcacacc	gaccccgcca	cgtgaggagc	atcttcgagc	agccgcagga	tccccgcgtc
	361	ttggcccgaga	gagggcgagg	gcaccgtttc	gtggaactgg	cgctgcgggg	cggtcggggc
10	421	tggtgtgacc	tgtgcggacg	agaggtgctg	cggcaggcgc	tgcgctgccc	taattgtaaa
	481	ttcacctgcc	actcggagtg	ccgcagcctg	atccagttgg	actgcagaca	gaagggggggc
	541	cctgccctgg	atagacgctc	tccaggaagc	acccctaccc	caaccttgaa	ccagaatgtc
	601	tgtaaggcag	tggaggagac	acagcaccgc	cccacgatac	aggagatcaa	gcagaagatt
	661	gacagctata	acagcaggga	gaagcactgc	ctgggcatga	agctgagtga	agatggcacc
15	721	tacacaggtt	tcatcaaagt	gcatttgaag	ctccgacggc	cagtgcagggt	gcccgcctgga
	781	tccggcccca	gtccatctat	ggatgccatt	aaggaaagtga	accctgcagc	caccacagac
	841	aagcggagct	ccctctacct	gccactcgat	gccatcaagc	agctacatat	cagcagcacc
	901	accacgggta	gtgagggtcat	ccaggggctg	ctcaagaagt	tcatgggtgt	ggacaaccca
	961	cagaagtttg	cacttttttaa	gcggatacac	aaagatggac	aagtgtctct	ccagaaactc
20	1021	tccattgctg	actatcctct	ctaccttcgt	ctgctcgctg	ggcctgacac	cgatgttctc
	1081	agctttgtgc	taaaggagaa	tgaaactgga	gaggtggagt	gggatgcctt	ttccattcct
	1141	gaactccaga	actttttaac	tatcctggaa	aaagaggagc	aggacaagat	ccatcaactg
	1201	caaaagaagt	acaacaaatt	ccgtcagaaa	ctggaagagg	cattacgaga	gtcccaaggg
	1261	aagccggggg	aaccagccga	cttcctgtcc	tctcagtgcc	ctccaattta	ttttattggt
25	1321	aattattttg	caacaaagag	ttactgttaa	gacacctctg	gtggttccac	cagtgcctcg
	1381	cccagcagtt	aacagatgtg	gcacaaagtc	tcttcacgac	agtgtctatg	cagggttcog
	1441	attcctgcta	accaccaca	ccatggctct	ggagagcttc	ccgcctggga	tcagaactcc
	1501	tgtggaatga	ccagtgtttc	cctgctcagt	ctgctggcct	ctcagaaacc	aaatagttgc
	1561	ctctctgggc	accaaactcc	aatcaatcac	cagccggcaa	aaggaaagaa	aggtttcaga
30	1621	gcctgtgtgt	tctttctctg	gatttactct	tcagttcctc	ttttggtttg	tttgggtggg
	1681	tttttttggc	cacgtatagt	atattttaagg	atcaaagtgt	gcataattcat	tctagctaag
	1741	tccttgaaag	caggaaaatg	ctcatgaaag	gactgtcctt	gccccaaagg	gcctcttctt
	1801	ctctagtact	agacactcag	ggtcagcctg	agatttcaag	aggctacagc	ctgaccaggc
	1861	cgtcttctta	ttaccagca	ggctgtgtgc	atgcaaaccc	aaagacatat	atgcacatct
35	1921	gtgtgggtatt	tcagcatgtc	tctgtccaat	gtttgatatg	ttaacatttg	aatttaaatgc
	1981	tgctctcctt	atgggtttct	accaaagaga	aaccagccac	ttatcaattt	tagtttcttg
	2041	ctgagctgcc	agaaagtatt	acagagaagc	acatccaagc	tgtctgtggc	ctacgcctgc
	2101	aggggggtgg	gggcctgaat	ctccttggcc	ttcagttcca	cctccacctc	tggttttagg
	2161	gtctccagct	gttgccctgag	tagtagcttt	gattacagcg	gtaaagtcc	ccaacttgga
40	2221	gtcctttctg	gtgggaagca	tggtctgctc	gcagcacagc	actgagcaga	cccgtgggcc
	2281	tgacttccct	ggtgacttca	gtgccttttt	gtttgcagag	aaaagagtgg	ggcactttgc
	2341	ttgaagctct	ctgctggctt	gcccctggca	ggaagtggac	aatggtgcta	tagagccaag
	2401	gacacagcct	cagagcacag	ggtgattgat	gacagcctc	tttcccatca	agcttcccg
	2461	tcaggctttg	actttgaaga	tgcgagggtta	ctagactgca	ttgacagcat	cagattatga
45	2521	ctccaaactct	tgagtagttc	agacttaaaa	ccaatcagcc	agagttagcca	ggactgcaaa
	2581	gacactcaat	acagatggag	aaaaacttgt	ccctttaaaa	gagggccagt	gtttcaattg
	2641	agcctccaga	ggagaccact	ttcatgttgt	gcttgccttt	ccataccctt	tctcgggtt
	2701	gttttaagcc	caagcttctc	cgtgtagcct	aaaaagttcc	ctaccagccc	agctgaagcc
	2761	acactgctcc	ogtccagaa	gaacgcaaaa	tccttgtcat	tcaaaactgtg	catcgtttgc
50	2821	agagctgcaa	aaagcaacat	gagctagcga	ctctgaggtt	gtgcacgcca	tcagcccctt
	2881	ggctgcctga	ggtctcatgc	ccagccttac	acctctctcc	cttaagaagc	ccccgtcctg
	2941	ctgtgtacta	caggggcacg	tggaatcatt	cccttcatcc	tgcattgtctg	tagcgtagg
	3001	agaaggcatg	gctcctgc				

MASPAIGQRP YPLLLDPEPP RYLSQSLGGTE PPPPARPRRC IPTALIPAAG ASEDRGGRRS  
 GRRDPEPTPR DCRHARVPR GLQPRRLRLRP GSHRPDRVRS IFEQPQDPRV LAERGEHHRF  
 VELALRGGPG WCDLCGREVL RQALRCANCK FTCHSECRSL IQLDCRQKGG PALDRRSPGS  
 TLTPTLNQNV CKAVEETQHP PTIQEIKQKI DSYNSREKHC LGMKLS EDTG YTGFIKVHLK  
 5 LRRPVTVPAG SGPSPSMDAI KEVNPAATTD KRTSFYLPD AIKQLHISST TTVSEVIQGL  
 LKKFMVVDNP QKFALFKRIH KDGQVLFQKL SIADYPLYLR LLAGPDTDLV SFVLKENETG  
 EVEWDAFSIP ELQNFLTILE KEEQDKIHL QKKYNKFRQK LEEALRESQG KPG

**VHL** GenBank Accession No. NM 000551

10 Nucleic acids: SEQ ID NO: 129 (coding 2145-855); Amino acids

1 cctcgccctcc gttacaacgg cctacgggtgc tggaggatcc ttctgcgccac ggcacacagcc  
 61 tccggcccgcc tatttcccgcg agcgcgttcc atcctctacc gagcgcgcgc gaagactacg  
 121 gaggtcgact cgggagcgcg cagcagctc cgcccccgcg ccgacccgcg gatccccgcg  
 181 cgtccggccc ggggtggtctg gatcgcgag ggaatgcccc ggaggcgcgga gaactgggac  
 15 241 gagggcgagg taggcgcgga ggaggcaggc gtcgaagagt acggccctga agaagacggc  
 301 ggggaggagt cgggcgcgga ggagtccggc ccggaagagt ccggcccgga ggaactgggc  
 361 gccgaggagg agatggaggc cgggcggcg cgcccgtgc tgcgctcggg gaactcgcg  
 421 gagccctccc aggtcatctt ctgcaatcgc agtcgcgcg tcgtgctgcc cgtatggctc  
 481 aacttcgacg gcgagccgca gccctaccca acgctgcgcg ctggcacggg ccgcccgcac  
 20 541 cacagctacc gaggtcacct ttggctcttc agagatgcag ggacacacga tgggtctctg  
 601 gttaaccaa ctgaattatt tgtgccatct ctcaatgttg acggacagcc tatttttggc  
 661 aatatcacac tgccagtgtat tactctgaaa gagcgatgcc tccaggttgt ccggagccta  
 721 gtcaagcctg agaattacag gacactggac atcgtcaggc cgtctacga agatctggaa  
 781 gaccaccaa atgtgcagaa agacctggag cggctgacac aggagcgcat tgcacatcaa  
 25 841 cggatgggag attgaagatt tctgttgaaa cttacactgt ttcatctcag cttttgatgg  
 901 tactgatgag tcttgatcta gatacaggac tgggttccttc cttagtctca aagtgtctca  
 961 ttctcagagt aaaataggca ccattgctta aaagaaagtt aactgacttc actaggcatt  
 1021 gtgatgttta ggggcaaaca tcacaaaatg taatttaatg cctgcccatt agagaagtat  
 1081 ttatcaggag aagggtggtg catttttgc tctagtaag tcaggacagc ttgtatgtaa  
 30 1141 ggaggtttgt ataagtaatt cagtgggaat tgcagcatat cgtttaatt taagaaggca  
 1201 ttggcatctg cttttaatgg atgtataata catccattct acatccgtag cggttggtga  
 1261 cttgtctgac tctgctttg ggaagactga ggcacccgtg aggcagggac aagtctttct  
 1321 cctctttgac accccagtgc ctgcacatca tgagccttca gtcagggttt gtcagaggaa  
 1381 caaacaggg gacactttgt tagaaagtgc ttagagggtc tgctctatt tttgtgggg  
 35 1441 ggtgggagag gggaccttaa aatgtgtaca gtgaacaaat gtcttaaagg gaatcatttt  
 1501 tgtaggaagc attttttata attttctaag tcgtgcactt tctcggtcca ctctgttgga  
 1561 agtgctgttt tattactgtt tctaaactag gattgacatt ctacagtgtg gataatagca  
 1621 tttttgtaac ttgccatccg cacagaaaat acgagaaaat ctgcatgttt gattatagta  
 1681 ttaatggaca aataagtttt tgctaaatgt gagtatttct gttccttttt gtaaatatgt  
 40 1741 gacattcctg attgatattg gttttttgt tgttgttgt ttgttttttt ttgttttttt  
 1801 gagatggagt ctcactcttg tcaccaggc tggagtgcag tggcgccatc tcggctcact  
 1861 gcaacctctg ctcctctggg tcaagtaatc ctctgagta gctgggatta caggcgctg  
 1921 caccacgct ggccaatttt tgtactttta gtagagacag tgtttcgcca tgttggccag  
 1981 gctggtttca aactcctgac ctgaggtgat ccgcccacct cagcctccca aaatgggtggg  
 45 2041 attacagggt tgtggggcac cgtgcctggc tgattcagca ttttttatca ggcaggacca  
 2101 ggtggcactt ccacctccag cctctggtcc taccatgga ttcattggag agcctggact  
 2161 gtttcatagt tttctaaatg tacaattct tataggctag acttagattc attaatcaa  
 2221 attcaatgct tctatcagac tcagtttttt gtaactaata gatttttttt tccacttttg  
 2281 ttctactcct tccctaatag ctttttaaaa aaatctcccc agtagagaaa catttgga  
 50 2341 agacagaaaa ctaaaaagga agaaaaaaga tccctattag atacacttct taaatacaat  
 2401 cacattaaca ttttgagcta tttccttcca gcctttttag ggcagatttt aacttggttt  
 2461 tacatagttg agattgtact gttcatacag ttttataccc tttttcattt aactttataa  
 2521 cttaaatatt gctctatgtt agtataagct tttcacaaac attagtatag tctccctttt  
 2581 ataattaatg tttgtgggta tttcttggca tgcactttta attccttctc ctagcctttg  
 55 2641 ggcacaattc ctgtgctcaa aaatgagagt gacggctggc atggtggctc ccgctgttaa  
 2701 tcccagtact ttgggaagcc aaggtaagag gattgcttga gcccagaact tcaagatgag

2761 cctgggctca tagtgagaac ccattctatac aaaaaatttt taaaaattag catggcgcca  
 2821 cacatctgta atcctagcta cttggcaggc tgagggtgaga agatcattgg agtttaggaa  
 2881 ttggaggctg cagttagcca tgagtatgcc actgcactcc agcctggggg acagagcaag  
 2941 accctgctc aaaaaaaaaa aaaaaaaaaa

MPRRAENWDE AEVGAEAGV EEYGPEEDGG EESGAEEESGP EESGPEELGA EEEMEAGRPR  
 PVLRVNSRE PSQVIFCNRS PRVVLVWLN FDGEQPYPT LPPGTGRRH SYRHLWLF  
 DAGTHDGLLV NQTELFVPSL NVDGQPIFAN ITLPVYTLKE RCLQVVRSLV KPENYRRLDI  
 VRSLYEDLED HPNVQKDLER LTQERIAHQR MGD

### **Experimental procedures**

#### **Family with CC-RCC and t(1;3)(q32.1;q13.3), paired CC-RCC tumors/normal kidney tissues, and cell lines**

The clinical and genetic details of the Japanese kindred with familial CC-RCC have been previously published (Kanayama *et al.*, 2001). The EBV-transformed lymphoblastoid cell lines FRCC3 and FRCC5 used in this study were established from two affected translocation carriers.

Four tumors were from three members of the t(1;3) family, and 53 matched pairs of CC-RCC were collected from the University of Tokushima in Japan.

Nine established RCC cell lines were purchased from ATCC: A-498, A-704, Caki-1, Caki-2, SW-839, ACHN, 786-O, 769-P, and SW-156.

#### **Construction of BAC contigs and FISH analyses**

Forty-four 1q32.1 and 3q13.3 BAC clones were obtained from the BACPAC Resource Center (Children's Hospital, Oakland Research Institute) or ResGen Invitrogen Corporation.

The clones were selected based on information in the BAC clone mapping databases and Human Genome Sequence Draft database. The details of the BACs are listed in the Supplemental Experimental Procedures.

Standard dual-color FISH was performed by hybridizing each of the 44 BAC clones to metaphase slides prepared from FRCC3 or FRCC5. In all hybridizations, the PAC clone 160H23 from the 1q subtelomere (Cytocell Ltd, UK) was included as a marker of the normal chromosome 1 and the der(3) chromosome.

#### **Long-range PCR, Southern blot analysis, and Northern blot analysis**

Long-range PCR was used for the amplification of the breakpoints and the generation of DNA probes for Southern blot analysis with an Advantage Genomic PCR kit (Clontech, USA).

PCR was carried out following the manufacturer's user manual. Southern blot and Northern blot analyses were performed following the standard protocol. Human multiple tissue Northern blots



were purchased from Clontech (Cat. #7780-1). Details of these analyses can be found in the Supplemental Experimental Procedures.

#### **Mutation analysis**

Mutation analysis of *LSAMP*, *NORE1A*, and *NORE1B* was performed in the 53 sporadic CC-RCCs and 9 RCC cell lines. Each exon of *LSAMP*, *NORE1A*, and *NORE1B* was amplified by PCR using primers derived from the flanking intronic or UTR sequences (see Table A in the Supplemental Data). The PCR products were then purified and subjected to direct DNA sequencing using PE Applied Biosystems.

#### **Real-time quantitative RT-PCR**

Total RNA from normal kidney tissues, RCC cell lines, and sporadic tumors was subjected to real-time quantitative PCR using an ABI PRISM 7700 Sequence Detection System. Specific primer and probe were designed for *LSAMP* and *NORE1A* using Primer Express v1.5a (Applied Biosystems). The primer sequences and the details of the real-time RT-PCR analysis are described in the Supplemental Experimental Procedures.

#### **DNA methylation analysis and demethylation treatment by 5-aza-2'-deoxycytidine (5-aza-CdR)**

Methylation analysis was performed for the promoter CpG islands of *LSAMP* and *NORE1A*. Bisulfite-PCR followed by restriction enzyme digestion analysis was used. Eight RCC cell lines were demethylated by 5-aza-CdR (Sigma, USA) treatment. The primers and the details of the analyses are given in the Supplemental Experimental Procedures.

#### **LOH analysis**

LOH detection for *LSAMP* and *NORE1* was performed by genotyping the 53 paired normal/tumor DNA samples. The microsatellite markers flanking the *LSAMP* locus are *D3S3681*, *D3S1271*, *D3S1267*, and *D3S1292*. *NORE1* locus markers include *D1S413* and *D1S249*. All the markers were obtained from ABI Prism Linkage Mapping Set version 2, panel 1 and 2 (Applied Biosystems). The details of LOH analysis are described in the supplemental experimental procedures.

#### **Cell growth assay**

Expression plasmids *pEGFP-LSAMP*, *-NORE1A*, and *-Nore1* were generated by ligating cDNAs of *LSAMP*, *NORE1A*, and murine *Nore1* to N- or C-terminal enhanced green fluorescent protein vectors (*pEGFP-N1/-C1*) (Clontech, USA). Expression plasmids were microinjected and transfected into two RCC cell lines, A-498 and/or Caki-1, for cell growth-suppression assay.

Inducible experiments and nuclear fractionation assays were also performed for the nuclear location of Nore1. Detailed methods are provided in the Supplemental Data.

**URLs.** University of California, Santa Cruz (UCSC) Human Genome Browser at the web site: [www.genome.ucsc.edu](http://www.genome.ucsc.edu); Discovery System Human Genome Browser: at the web site: [www.cds.celera.com](http://www.cds.celera.com); Human Genome Browser NCBI: at the web site [ncbi.nlm.nih.gov](http://ncbi.nlm.nih.gov).

### **Supplemental Experimental Procedures**

#### **BAC clones used for construction of BAC contigs and FISH analyses**

The 20 BAC clones from 1q32.1 are RP11-196B7, RP11-70G20, RP11-219P13, RP11-45F21, RP11-104A2, RP11-124A11, RP11-149C8, RP11-237N7, RP11-142B3, RP11-421E17, RP11-54L22, RP11-262N9, RP11-237C22, RP11-145I13, RP11-57I17, RP11-534L20, CTD-2245C1, CTD-2321B11, CTD-2278G17, and RP11-343H5.

The 24 BAC clones from 3q13.3 are RP11-138N21, RP11-58D2, RP11-324H4, RP11-165B13, RP4-635B5, RP11-484M3, RP11-829I14, RP11-641I23, RP11-643A3, RP11-891J4, RP11-281N16, RP11-50N14, RP11-728O20, RP11-899P8, RP11-716E6, RP11-1115L2, RP11-60P15, RP11-47C16, CTD-2246M24, RP11-149B11, CTD-2514L8, CTD-2016D14, CTC-804P8, and CTC-2006J5.

#### **Long-range PCR, Southern blot analysis, and Northern blot analysis**

Long-range PCR was used for the amplification of the breakpoints and the generation of DNA probes for Southern blot analysis with an Advantage Genomic PCR kit (K1906-Y, CLONTECH Laboratories, Inc., USA). PCR was carried out following the manufacturer's user manual. BAC clones spanning the 1q32.1 (RP11-54L22) and 3q13.3 (RP11-281N16) breakpoints were used as PCR templates. Four approximately 10-kb and five 4- to 6-kb DNA probes were synthesized for 1q breakpoint mapping and six 5- to 7-kb DNA probes were generated for Southern blot analysis in 3q breakpoint mapping. Two EBV-transformed lymphoblastoid cell lines of two patients from the t(1q;3q) family and two normal EBV-transformed lymphoblastoid cell lines were used for Southern blot analysis. Fifteen microgram aliquots of genomic DNA were digested using *Bam*HI, *Eco*RI, *Hind*III, *Stu*I, *Eco*RV, *Xba*I, *Bgl*II, and *Bgl*III. Completely digested DNA samples were separated by size on a 0.8% agarose in 1 × TBE buffer. Southern blot to nylon membrane and subsequent hybridization were performed following the standard protocol.

For Northern blot analysis, human multiple tissue Northern blots were purchased from Clontech (USA, Cat. #7780-1). Northern blots were also prepared with RNA from normal

kidney (Clontech) and with RNA extracted from the nine RCC cell lines, the EBV lines FRCC3 and FRCC5, two EBV lines from normal individuals, and normal kidney tissues from two patients with sporadic CC-RCC. Total RNA was extracted using the Trizol Reagent kit (Invitrogen), and 15 µg of total RNA of each sample was for the Northern blots. Probes specific for *NORE1A* (exon 1α), *NORE1B* (exon 2β), *LSAMP* (exon 1), and β-actin were synthesized by PCR labeled with α-<sup>32</sup>P and hybridized to the Northern filters under stringent conditions.

#### RT-PCR

RT-PCR was performed using 5 µg of total RNA isolated from the nine RCC cell lines and nine normal kidney tissues, Superscript-II RT (Invitrogen), random hexamer primers, and specific primer pairs. Specific primers from *LSAMP* and *NORE1A* were used for fusion transcripts analysis. The primer sequences are given in Table A of supplemental data online. PCR was carried out at 95°C for 5 min, followed by 95°C for 30 s, 58°C for 30 s and 72°C for 45 s, for 35 cycles.

#### LOH analysis

PCR was performed according to the manufacturer's protocol. For each individual, 1 µl of PCR product from each marker was then pooled. One microliter of this mixture was added to 10 µL of Hi-Di formamide and 0.1 µl of ROX 400HD size standard and denatured at 95 °C for 5 min before loading the samples into an ABI Prism 3700 DNA Analyzer (Applied Biosystems). Analysis of raw data and assessment of LOH were performed with Genescan v. 3.7 and Genotyper v. 3.7 software, respectively (Applied Biosystems). LOH was defined according to the following formula: LOH index = (T2/T1)/(N2/N1), where T was the tumour sample, N was the matched normal sample, and 1 and 2 were the intensities of smaller and larger alleles, respectively. If the ratio was less than 0.67 or more than 1.3, the result was determined to be LOH.

#### Real-time quantitative RT-PCR

Two micrograms of total RNA from 9 normal kidney tissues, the 9 RCC cell lines, and 16 sporadic tumors with *LSAMP* and/or *NORE1A* promoter methylation (RNA from other tumors was not available for analysis) were reverse-transcribed in a 100 µl reaction mixture using MultiScribe Reverse Transcriptase following the manufacturer's instruction (Applied Biosystems). Real-time quantitative PCR was performed using an ABI PRISM 7700 Sequence Detection System. Specific primer and probe sequences were designed for *LSAMP* and *NORE1A* using Primer Express v1.5a (Applied Biosystems).

*LSAMP* forward primer: 5'-CAATGGCCGTCCTGAACCT-3' (SEQ ID NO:106);

*LSAMP* reverse primer: 5'-CAAATTCCTTCCAGTTGGTGTA-3' (SEQ ID NO:107);

*LSAMP* Taqman probe: 5'-6FAM-TTATCACCTGGAGACACC-MGBNFQ (SEQ ID NO:108);

*NORE1A* forward primer: 5'-GCGCTGCACTAACTGTAAATTCA-3' (SEQ ID NO:109);

5 *NORE1A* reverse primer: 5'-GGGATAAACCTCCTGCTGACT-3' (SEQ ID NO:110);

*NORE1A* taqman probe: 5'-6FAM-TCACCCAGAATGCCGCA-MGBNFQ-3' (SEQ ID NO:111).

Of each sample, 100 ng was amplified using the following PCR conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. A series of five 1:2 dilutions of pooled normal sample served as a standard curve for relative quantification. Each tumor sample was normalized to an endogenous control,  $\beta$ -actin, and then normalized to the standard curve. Reported are values of fold change from pooled normal.

#### DNA methylation analysis

Two  $\mu$ g of genomic DNA from each cell line, tumor and normal kidney tissue was denatured in 0.3 M NaOH for 15 min at 37°C. Cytosines were sulfonated in 5 mM hydroquinone (Sigma) and 3.12 M sodium bisulfite (Sigma) for 16 h at 50°C. The DNA samples were desalted through columns, desulfonated in 0.3 M NaOH and precipitated with ethanol. DNA sequences were amplified by nested PCR. Approximately 50 ng of bisulfite-treated DNA was firstly amplified in a reaction volume of 30  $\mu$ l with respective outer primer pairs:

*LSAMP-BISF-OF* (5'-TGGTAGAGGAGTATTTAGTTATAGAGAGA-3') (SEQ ID NO:112),

20 *LSAMP-BISF-OR1* (5'-TCTCAATAAAACCAATAACAACCTATTTTC-3') (SEQ ID NO:113),

*NORE1A-BISF-OF2* (5'-AAGAGGTAGGGTTGAAGGTTTAGGGTTT-3') (SEQ ID NO:114), and

*NORE1A-BISF-OR2* (5'-CTCRAAACCRCCTCAAACCTCTATAAATAAC-3') (SEQ ID NO:115).

PCR was carried out at 95°C for 8 min, followed by 95°C for 30 s, 58°C for 30 s and 72°C for 1 min, for 30 cycles. A nested PCR was performed using 1  $\mu$ l of the initially amplified products and the respective internal primer pairs:

*LSAMP-BISF-IF* (5'-TGTTTGGGTTTTATGAGGGTTTTGT-3') (SEQ ID NO:116) and

*LSAMP-BISF-IR* (5'-CRACTAACTCTCCTAACCATAATAACCAC-3') (SEQ ID NO:117),

*NORE1A-BISF-IF2* (5'-GAATTTTGTAGTTGTTTTAGGTGAAGA-3') (SEQ ID NO:118), and

*NORE1A-IR2* (5'-CRACRACTCRAAATCCAATAATAA-3') (SEQ ID NO:119)

30 with similar conditions as described for the preceding PCR amplification. The PCR products were purified using Microcon YM-100 (Millipore Corporation, USA). For isoform *NORE1B*, methylation analysis was performed as described in Tommasi *et al.* 2002. For restriction enzyme

analysis of PCR products from bisulfite-treated DNA, 30 ng of the PCR products was digested with 10 units of *TaqI* (Invitrogen, USA) and separated by size on a 2.0% TAE gel.

#### **Demethylation of LSAMP and NORE1A by 5-aza-2'-deoxycytidine (5-aza-CdR) treatment**

Eight RCC cell lines (except the slow-growing A-704 cell line) were subjected to 5-aza-CdR (Sigma Chemical Co., St. Louis, MO) treatment. Approximately  $5 \times 10^5$  cells for each line were seeded on a 100-mm plate and incubated for 24 h. The cells were cultured up to 14 d in complete media which contained 2.5  $\mu$ M of 5-aza-CdR, and media was changed at 2-d intervals. Isolated total cellular RNAs from RCC cell lines treated and untreated with 5-aza-CdR were analyzed with real-time quantitative RT-PCR.

#### **Cell growth assay**

RCC cell lines A-498 and/or Caki-1, growing logarithmically on glass coverslips and maintained in 10% fetal calf serum, were microinjected or lipid-mediated transfection with *pEGFP-LSAMP*, *pEGFP-NORE1A*, *pEGFP-Nore1* or the vector control *pEGFP-C1/pEGFP-N1* (50 ng/ml). Two hours after injection or 24 h after lipid-mediated transfection (Lipofectamine2000 reagents, Invitrogen), EGFP/EGFP-Nore1-expressing cells were fixed and stained with Texas Red-labeled phalloidin to reveal F-actin architecture and Hoechst 33342 (blue) to visualize DNA (nuclei). To monitor proliferation in cells expressing EGFP-LSAMP, EGFP-NORE1A, and Nore1 fusion proteins or EGFP, 40-60 cells were microinjected with expression plasmids for the indicated protein, and returned to the incubator for 2 h. The number of successfully injected/expressing cells were then counted on an inverted epifluorescence microscope and thereafter at the selected times.

#### **Supplemental inducible experiments and nuclear fractionation assay for nuclear location of Nore1**

To confirm the nuclear location of Nore1, we performed experiments by cloning Nore1 into the pIND(SP1)-Hygro vector (Invitrogen, Carlsbad, CA) and transfecting the plasmid into 293-T cells using Lipofectamine2000 reagents (Invitrogen). After selection in hygromycin, cell populations were pooled at an early passage and assayed for the effects of Nore1 induction on cell proliferation by growth curve analysis. Selected cells were plated at a cell density of  $2.5 \times 10^5$  cells/well in triplicate and induced with Ponasterone A 24 h later. Cells were counted using a Coulter counter every 24 h. Western analysis was performed on lysates at each time point.

For nuclear fractionation assay, 293-T cells were transfected with 1  $\mu$ g of pcDNAFlag-Nore1 using CaPO4 (Invitrogen, Carlsbad CA). Forty-eight hours later cells were harvested and

processed for subcellular fractionation. Protein determinations were made for each fraction and equivalent amounts were loaded on to gel. The cytoplasmic, membrane and nuclear fractions were then subjected to Western analysis using an anti-FLAG antibody (Sigma, St. Louis, MO).

### References for Examples

- 5 Bodmer, D *et al.*, (2002a). Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). *Hum. Mol. Genet.* 11, 641-649.
- Bodmer, D. *et al.*, (2002b). Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21). *Cancer Genet. Cytogenet.* 134, 6-12.
- 10 Bodmer, D. *et al.*, (1998). An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. *Am. J. Hum. Genet.* 62, 1475-1483.
- Bodmer, D., *et al.* (2002c). Understanding familial and non-familial renal cell cancer. *Hum. Mol. Genet.* 11, 2489-2498.
- Carpten, J. D. *et al.*, *Nat. Genet.* 32, 676-680.
- 15 Cohen, A.J. *et al.* (1979). Hereditary renal-cell carcinoma associated with a chromosomal translocation. *N. Engl. J. Med.* 301, 592-595.
- Dammann, R. *et al.* (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. *Nat. Genet.* 25, 315-319.
- Dreijerink, K *et al.* (2001). The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. *Proc. Natl. Acad. Sci. USA* 98, 7504-7509.
- 20 Druck, T. *et al.* (1997). Structure and expression of the human FHIT gene in normal and tumor cells. *Cancer Res* 57, 504-512.
- Druck, T. *et al.* (2001). The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. *J. Hum. Genet.* 46, 583-589.
- 25 Eleveld, M.J. *et al.* (2001). Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). *Genes Chromosomes Cancer* 31, 23-32.
- Gemmill, R.M. *et al.*, (2002). The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. *Oncogene* 21, 3507-3516.
- Hesson, L. *et al.* (2003). NORE1A, a homologue of RASSF1A tumor suppressor gene is inactivated in human cancers. *Oncogene* 22, 947-954.
- 30 Jones, P.A. *et al.* (2002). The fundamental role of epigenetic events in cancer. *Nat. Rev. Genet.* 3, 415-428.
- Kanayama, H. *et al.* (2001). Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma, *J. Med. Genet.* 38, 165-170.
- Khokhlatchev, A. *et al.* *Curr. Biol.* 12, 253-265.
- 35 Koolen, M.I. *et al.* (1998). A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. *Kidney Int.* 53, 273-275.
- Kovacs, G. *et al.*. (1989). Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. *Int. J. Cancer* 43, 422-427.
- 40 Kovacs, G. *et al.* (1988). Loss of der(3) in renal carcinoma cells of a patient with constitutional t(3;12). *Hum Genet* 78, 148-150.

- Latif, F. *et al.* (1993). Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 260, 1317-1320.
- Morrissey, C *et al.* (2001). Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. *Cancer Res.* 61, 7277-7281.
- 5 Nickerson, M.L. *et al.* (2002). Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. *Cancer Cell* 2, 157-164.
- Ohta, M. *et al.* (1996). The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. *Cell* 84, 587-597.
- 10 Ortiz-Vega, S. *et al.* (2002). The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. *Oncogene* 21, 1381-1390.
- Pimenta, A.F. *et al.* (1996). cDNA cloning and structural analysis of the human limbic-system-associated membrane protein (LAMP). *Gene* 170, 189-195.
- Podolski, J. *et al.* (2001). Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. *J. Hum. Genet.* 46, 685-693.
- 15 Schmidt, L. *et al.* (1995). Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. *Cancer J. Sci. Am.* 1, 191.
- Sellar, G. C. *et al.* (2003). OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. *Nat. Genet.* 34, 337-343.
- 20 Siprashvili, Z. *et al.* (1997). Replacement of Fhit in cancer cells suppresses tumorigenicity. *Proc Natl Acad Sci U S A* 94, 13771-13776.
- Storkel, S *et al.* (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer* 80, 987-989.
- Teh, B.T. *et al.* (1997). Familial non-VHL non-papillary clear-cell renal cancer. *Lancet* 349, 848-849.
- 25 Tomlinson, I.P. *et al.* (2002). Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat. Genet.* 30, 406-410.
- Tommasi, S. *et al.* (2002). RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. *Oncogene* 21, 2713-2720.
- van den Berg, A. *et al.* (1997). Involvement of multiple loci on chromosome 3 in renal cell cancer development. *Genes Chromosomes Cancer* 19, 59-76.
- 30 van Kessel, A.G. *et al.* (1999). Renal cell cancer: chromosome 3 translocations as risk factors. *J. Natl. Cancer Inst.* 91, 1159-1160.
- Vavvas, D. *et al.* (1998). Identification of Nore1 as a potential Ras effector. *J. Biol. Chem.* 273, 5439-5442.
- 35 Vos, M.D. *et al.* (2000). Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. *J. Biol. Chem.* 275, 35669-35672.
- Woodward, B.R. *et al.* (2000). Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. *J. Med. Genet.* 37, 348-353.
- Yoon, J.H. *et al.* (2001). Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. *Int. J. Cancer* 94, 212-217.
- 40 Zbar, B. *et al.* (2003). Studying cancer families to identify kidney cancer genes. *Annu. Rev. Med.* 54, 217-233.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make changes and modifications of the invention to adapt it to various usage and conditions.

5 Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The entire disclosure of all applications, patents and publications, cited above and in the figures are hereby incorporated in their entirety by reference.



WHAT IS CLAIMED IS:

1. A method for detecting the presence of clear cell renal cell carcinoma (CC-RCC) in a subject, or the susceptibility of the subject for developing CC-RCC comprising detecting or measuring LSAMP and/or NORE1 gene expression in a sample from the subject, and comparing the expression with a baseline level of expression, wherein a reduction in the expression of one or both of said genes compared to the baseline level indicates that the subject suffers from, or is susceptible to CC-RCC.
2. The method of claim 1 wherein the expression is detected or measured as transcription of mRNA encoded by the LSAMP and/or NORE1 gene, by detecting or measuring the presence or amount of said mRNA in said sample.
3. The method of claim 1 wherein the expression is detected or measured as a polypeptide product encoded by the LSAMP or NORE1 gene, by detecting or measuring the presence or amount of LSAMP or NORE1 polypeptide in said sample.
4. The method of claim 3 wherein said detecting or measuring is performed with a binding partner for said LSAMP1 or NORE1 polypeptide.
5. The method of claim 4 wherein said binding partner is an antibody specific for an epitope of said LSAMP1 or NORE1 polypeptide and said detecting or measuring is by an immunoassay.
6. The method of any of claims 1-5 wherein said sample is a cell, tissue or tissue extract.
7. The method of any of claims 1-5 wherein said sample is a body fluid selected from the group consisting of blood, plasma, serum, urine, saliva or cerebrospinal fluid.
8. The method of claim 7 wherein said sample is a kidney tumor.
9. The method of claim 8 wherein said sample is section of a paraffin embedded tissue section of said kidney tumor.

10. A method for inhibiting a cancer-associated property of a cell in which the expression of the *LSAMP* and/or *NORE1* genes is reduced compared to a baseline value, comprising providing to the cell an effective amount of *LSAMP* and/or *NORE1* polypeptide or active fragment or variant thereof, wherein said polypeptide fragment or variant augments the level of *LSAMP* and/or *NORE1* gene products in the cell, thereby inhibiting said cancer-associated property.

11. The method of claim 10 wherein the providing is by microinjection, liposome-mediated introduction, or electroporation.

12. A method for inhibiting a cancer-associated property of a cell in which the expression of the *LSAMP* and/or *NORE1* genes is reduced compared to a baseline value, comprising providing to the cell an effective amount of

- (a) an *LSAMP* and/or *NORE1* polypeptide or active fragment or active variant thereof;
- (b) an expressible polynucleotide encoding said *LSAMP* and/or *NORE1* polypeptide, fragment or variant; or
- (c) an agent that induces or increases expression of the *LSAMP* and/or *NORE1* genes;

wherein said polypeptide, fragment or variant, said polynucleotide or said agent results in an increased level of *LSAMP* and/or *NORE1* gene products in the cell, thereby inhibiting said cancer-associated property.

13. The method of claim 12 wherein said property is tumor growth.

14. The method of claim 12 wherein the providing is by microinjection, liposome-mediated transfer, electroporation or microinjection.

15. A method for treating a subject with CC-RCC in whom CC-RCC cells under-express the *LSAMP* and/or the *NORE1* gene compared to a baseline value, which method comprises administering to the subject an effective amount of

- (a) an *LSAMP* and/or *NORE1* polypeptide or active fragment or active variant thereof;
- (b) an expressible polynucleotide encoding said *LSAMP* and/or *NORE1* polypeptide, fragment or variant; or

- (c) an agent that induces or increases expression of the *LSAMP* and/or *NORE1* genes;

wherein said polypeptide, fragment or variant, said polynucleotide or said agent results in an increased level of *LSAMP* and/or *NORE1* gene product in the under-expressing CC-RCC cells, thereby treating said subject.

16. The method of claim 15, wherein the polypeptide, active fragment, active variant, or agent is administered systemically or intratumorally.

17. The method of claim 15 wherein the polynucleotide being administered comprises a sequence encode the polypeptide, fragment or variant operably linked to an expression control sequence which promotes or induces expression of the polypeptide in said subject.

18. The method of claim 15 or 17 wherein the polynucleotide is administered by injection, by gene gun administration, or by needle-free jet injection.

19. The method of claim 18 wherein the polynucleotide is administered intramuscularly or intratumorally.

20. A pharmaceutical composition comprising

- (a) as an active moiety, an *LSAMP* and/or *NORE1* polypeptide, or an active fragment or variant thereof, or a polynucleotide encoding an *LSAMP* and/or *NORE1* polypeptide, or encoding an active fragment or variant of the polypeptide, wherein the polynucleotide is operably linked to an expression control sequence; and
- (b) a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20 wherein the active moiety is said polynucleotide.

22. A kit, suitable for a method of detecting the presence and/or measuring amount of an *LSAMP* and/or a *NORE1* polypeptide in a sample, comprising one or more reagents for detecting the polypeptide, and optionally

23. The kit of claim 22 wherein said detecting reagent is an antibody specific for an epitope of the *LSAMP* or *NORE1* polypeptide.

24. The kit of claim 23 further comprising one or more reagents for testing the binding of the antibody to a sample polypeptide and/or for facilitating detection of antibody binding.

25. A kit useful in a method detecting the presence and/or amount of a polynucleotide encoding LSAMP and/or NORE1 polypeptide in a sample, comprising a nucleic acid probe specific for a LSAMP- or NORE1-encoding DNA or RNA, and, optionally, one or more reagents that facilitate hybridization of the probe to the sample DNA or RNA, and/or that facilitate detection of the hybridized probe.

26. A kit useful in a method for treating a subject with CC-RCC, comprising


- (a) an LSAMP and/or NORE1 polypeptide or active fragment or active variant thereof;
- (b) an expressible polynucleotide encoding said LSAMP and/or NORE1 polypeptide, fragment or variant; or
- (c) an agent that induces or increases expression of the *LSAMP* and/or *NORE1* genes;

and optionally, (i) a means for administering the polypeptide to the subject and (ii) instructions for using the kit.

27. The kit of any of claims 21-26 comprising any one or more of: instructions for performing the method for which the kit is intended and/or for analyzing and/or evaluating the results of the method, a support on which a cell can be propagated, a support to which a reagent used in the method is immobilized, suitable buffers, media components, or other reagents for performing suitable controls, a computer, a computer-readable medium for storing and/or evaluating the assay results, containers or packaging materials.

28. An antibody specific for an epitope of the LSAMP or a NORE1 polypeptide which is useful in a the method of claim 5.

### Figure 1



**Figure 2**






Figure 3



A/7

Figure 4

A



B







FIGURE 5



6/7




FIG. 6A




FIG. 6B

FIGURE 6

FIGURE 7

